

EAU Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS)

M. Babjuk (Chair), A. Böhle, M. Burger, E. Compérat,
E. Kaasinen, J. Palou, M. Rouprêt, B.W.G. van Rhijn,
S.F. Shariat, R. Sylvester, R. Zigeuner
Guidelines Associates: O. Capoun, D. Cohen,
V. Hernández, V. Soukup

TABLE OF CONTENTS

PAGE

1.	INTRODUCTION	4
	1.1 Aim and scope	4
	1.2 Panel composition	4
	1.3 Available publications	4
	1.4 Publication history and summary of changes	4
	1.4.1 Publication history	4
	1.4.2 Summary of changes	4
	1.4.2.1 Changes in recommendation	4
	1.4.2.2 Summary of evidence	5
2.	METHODS	5
	2.1 Data Identification	5
	2.2 Review	6
	2.3 Future goals	6
3.	EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY	6
	3.1 Epidemiology	6
	3.2 Aetiology	6
	3.3 Pathology	7
	3.4 Summary of evidence	7
4.	STAGING AND CLASSIFICATION SYSTEMS	7
	4.1 Definition of non-muscle-invasive bladder cancer	7
	4.2 Tumour, Node, Metastasis Classification (TNM)	7
	4.3 Histological grading of non-muscle-invasive bladder urothelial carcinomas	8
	4.4 CIS and its classification	8
	4.5 Inter- and intra-observer variability in staging and grading	9
	4.6 Further promising pathology parameters	9
	4.7 Summary of evidence – classification	9
	4.8 Recommendations for bladder cancer classification	9
5.	DIAGNOSIS	10
	5.1 Patient history	10
	5.2 Signs and symptoms	10
	5.3 Physical examination	10
	5.4 Imaging	10
	5.4.1 Computed tomography urography and intravenous urography	10
	5.4.2 Ultrasound (US)	10
	5.5 Urinary cytology	10
	5.6 Urinary molecular marker tests	10
	5.7 Potential application of urinary cytology and markers	11
	5.7.1 Screening of the population at risk of bladder cancer	11
	5.7.2 Exploration of patients after haematuria or other symptoms suggestive of bladder cancer (primary detection)	11
	5.7.3 Surveillance of NMIBC	11
	5.7.3.1 Follow-up of high-risk NMIBC	11
	5.7.3.2 Follow-up of low/intermediate-risk NMIBC	11
	5.8 Cystoscopy	11
	5.9 Summary of evidence – primary assessment of NMIBC	12
	5.10 Recommendations for the primary assessment of NMIBC	12
	5.11 Transurethral resection of Ta, T1 bladder tumours	12
	5.11.1 Strategy of the procedure	12
	5.11.2 Office-based fulguration	13
	5.11.3 New resection techniques	13
	5.11.4 Bladder and prostatic urethral biopsies	13
	5.12 New methods of tumour visualisation	13
	5.12.1 Photodynamic diagnosis (fluorescence cystoscopy)	13
	5.12.2 Narrow-band imaging	14

5.13	Second resection	14
5.14	Pathology report	14
5.15	Summary of evidence - TURB and pathology report	14
5.16	Recommendations for TURB and/or biopsies and pathology report	14
6.	PREDICTING DISEASE RECURRENCE AND PROGRESSION	15
6.1	Ta, T1 tumours	15
6.2	Carcinoma in situ	17
6.3	Patient stratification into risk groups	17
6.4	Summary of evidence - stratification of NMIBC	18
6.5	Recommendations for stratification of NMIBC	18
7.	DISEASE MANAGEMENT	18
7.1	Counselling of smoking cessation	18
7.2	Adjuvant treatment	19
7.2.1	Intravesical chemotherapy	19
7.2.1.1	A single, immediate, post-operative intravesical instillation of chemotherapy	19
7.2.1.2	Additional adjuvant intravesical chemotherapy instillations	19
7.2.1.3	Options for improving efficacy of intravesical chemotherapy	19
7.2.1.3.1	Adjustment of pH, duration of instillation, and drug concentration	19
7.2.1.3.2	Microwave-induced hyperthermia and electromotive drug administration (EMDA)	20
7.2.1.4	Summary of evidence - intravesical chemotherapy	20
7.2.2	Intravesical bacillus Calmette-Guérin (BCG) immunotherapy	20
7.2.2.1	Efficacy of BCG	20
7.2.2.2	BCG strain	20
7.2.2.3	BCG toxicity	20
7.2.2.4	Optimal BCG schedule	22
7.2.2.5	Optimal dose of BCG	22
7.2.2.6	Indications for BCG	22
7.2.2.7	Summary of evidence - BCG treatment	22
7.2.3	Combination therapy	23
7.2.4	Specific aspects of treatment of CIS	23
7.2.4.1	Treatment strategy	23
7.2.4.2	Cohort studies on intravesical BCG or chemotherapy	23
7.2.4.3	Prospective randomised trials on intravesical BCG or chemotherapy	23
7.2.4.4	Treatment of CIS in prostatic urethra and upper urinary tract	23
7.2.4.5	Summary of evidence – treatment of CIS	23
7.3	Treatment of failure of intravesical therapy	25
7.3.1	Failure of intravesical chemotherapy	25
7.3.2	Recurrence and failure after intravesical BCG immunotherapy	25
7.3.3	Treatment of BCG failure and recurrences after BCG	25
7.3.4	Summary of evidence - treatment failure of intravesical therapy	25
7.4	Radical cystectomy for NMIBC	26
7.5	Recommendations for adjuvant therapy in Ta, T1 tumours and for therapy of CIS	27
7.6	Treatment recommendations in Ta, T1 tumours and CIS according to risk stratification	28
7.7	Treatment recommendations for BCG failure and recurrences after BCG	28
8.	FOLLOW-UP OF PATIENTS WITH NMIBC	29
8.1	Summary of evidence - follow-up of patients with NMIBC	29
8.2	Recommendations for follow-up in patients after TURB of NMIBC	30
9.	REFERENCES	30
10.	CONFLICT OF INTEREST	45

1. INTRODUCTION

1.1 Aim and scope

This overview represents the updated European Association of Urology (EAU) guidelines for Non-muscle-invasive Bladder Cancer (NMIBC) Ta, T1 and CIS. The information presented is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical guidance on the clinical management of NMIBC with a focus on clinical presentation and recommendations.

Separate EAU guidelines documents are available addressing upper tract urothelial carcinomas (UTUCs) [1], muscle-invasive and metastatic bladder cancer (MIBC) [2], and primary urethral carcinomas [3]. It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account.

1.2 Panel composition

The EAU Guidelines Panel on NMIBC consists of an international multidisciplinary group of clinicians, including a pathologist and a statistician. Members of this panel have been selected based on their expertise and to represent the professionals treating patients suspected of harbouring bladder cancer.

All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: <https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/>.

1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and in a number of versions for mobile devices, presenting the main findings of the NMIBC Guidelines. These are abridged versions which may require consultation together with the full text version. Several scientific publications are available, as are a number of translations of all versions of the EAU NMIBC Guidelines. All documents can be accessed on the EAU website.

1.4 Publication history and summary of changes

1.4.1 Publication history

The EAU Guidelines on Bladder Cancer were first published in 2000. This 2016 NMIBC guidelines document presents a limited update of the 2015 full text document.

1.4.2 Summary of changes

Key changes in this 2016 print:

1.4.2.1 Changes in recommendation

- In Section 5.16 – a recommendation has been added:

Recommendations for TURB and/or biopsies, tumour classification and pathology report	GR
In patients suspected of harbouring bladder cancer TURB followed by pathology investigation of the obtained specimen(s) is recommended as a diagnostic procedure and initial treatment step.	A

TURB = transurethral resection of the bladder.

- Section 7.2.1.1 - A single, immediate, post-operative intravesical instillation of chemotherapy – has been expanded to include the findings of systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation? [4].
- The recommendations as presented in Section 7.5 and Table 7.6 - Treatment recommendations in Ta, T1 tumours and CIS according to risk stratification - have been adapted. The recommendation grade did not change.

Section 7.5 Recommendations for adjuvant therapy in Ta, T1 tumours and for therapy of CIS	GR
In patients with tumours presumed to be at low risk and in those presumed to be at intermediate risk with previous low recurrence rate (less than or equal to one recurrence per year) and expected EORTC recurrence score < 5, one immediate chemotherapy instillation is recommended.	A

CIS = carcinoma in situ; EORTC = European Organization for Research and Treatment of Cancer.

Table 7.6 - Treatment recommendations in Ta, T1 tumours and CIS according to risk stratification

Risk category	Definition	Treatment recommendation
Intermediate-risk tumours	All cases between categories of low and high risk	In patients with previous low recurrence rate (less than or equal to one recurrence per year) and expected EORTC recurrence score < 5, one immediate instillation of intravesical chemotherapy after TURB. In all patients either 1-year full-dose BCG treatment (induction plus 3-weekly instillations at 3,6 and 12 months), or instillations of chemotherapy (the optimal schedule is not known) for a maximum of 1 year.

BCG = Bacillus Calmette-Guérin; EORTC = European Organization for Research and Treatment of Cancer; TURB = transurethral resection of the bladder.

1.4.2.2 Summary of evidence

- Section 3.4 - A summary of evidence has been added to Chapter 3 – Epidemiology, aetiology and pathology.
- Section 4.7 – A summary of evidence has been added to Chapter 4 – Staging and classification systems.
- Section 5.15 - Summary of evidence has been added to Chapter 5 – Diagnosis.
- Section 6.4 – A summary of evidence has been added to Chapter 6 – Predicting disease recurrence and progression.
- Section 7.2.1.4 – A summary of evidence has been added to Section 7.2.1 Intravesical chemotherapy.
- Section 7.2.2.7 – A summary of evidence has been added to Section 7.2.2 Intravesical bacillus Calmette Guérin immunotherapy.
- Section 7.2.4.5 – A summary of evidence has been added to Section 7.2.4 Specific aspects of treatment of CIS.
- Section 7.3.4 – A Summary of evidence has been added to Section 7.3 Treatment failure of intravesical therapy.

2. METHODS

2.1 Data Identification

For the 2016 NMIBC Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature.

A broad and comprehensive scoping exercise covering all areas of the NMIBC Guidelines was performed. The search was limited to studies representing high levels of evidence only (i.e. systematic reviews with meta-analysis, randomised controlled trials, and prospective non-randomised comparative studies only) published in the English language. The search was restricted to articles published during the period from 1st April 2014 to 31st May 2015. Databases covered by the search included Medline, EMBASE and the Cochrane Libraries. A total of 1,040 unique records were identified, retrieved and screened for relevance. A detailed search strategy is available on line:

<https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/?type=appendices-publications>.

A section of the text has been updated based on a systematic review and individual patient data meta-analysis:

- Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? [4] (Section 7.2.1.1).

Recommendations in this text are assessed according to their level of evidence (LE) and Guidelines are given a grade of recommendation (GR), according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [5]. Additional methodology information can be found in the general Methodology section of this print, and online at the EAU website: <http://uroweb.org/guidelines/>.

A list of Associations endorsing the EAU Guidelines can also be viewed on line at the above address.

2.2 Review

The following section was peer reviewed prior to publication:

- Chapter 7 – Disease management

The other sections of the NMIBC Guidelines were peer-reviewed in 2015.

2.3 Future goals

The results on ongoing and new systematic reviews will be included in the 2017 update of the NMIBC Guidelines. These reviews are performed using standard Cochrane systematic review methodology; <http://www.cochranelibrary.com/about/about-cochrane-systematic-reviews.html>.

Ongoing systematic reviews:

1. Is there a difference between the 2004 WHO grading system and the 1973 WHO grading system for NMIBC in terms of prognostic performance? [6].
2. Is there a difference between the 2004 WHO grading system and the 1973 WHO grading system for NMIBC in terms of reproducibility?

3. EPIDEMIOLOGY, AETIOLOGY AND PATHOLOGY

3.1 Epidemiology

Bladder cancer (BC) is the 7th most commonly diagnosed cancer in the male population worldwide, while it drops to 11th when both genders are considered [7]. The worldwide age-standardised incidence rate (per 100,000 person/years) is 9.0 for men and 2.2 for women [7]. In the European Union (EU), the age-standardised incidence rate is 19.1 for men and 4.0 for women [7]. In Europe, the highest age-standardised incidence rate has been reported in Belgium (31 in men and 6.2 in women) and the lowest in Finland (18.1 in men and 4.3 in women) [7].

Worldwide, BC age-standardised mortality rate (per 100,000 person/years) was 3.2 for men vs. 0.9 for women in 2012 [7]. Bladder cancer incidence and mortality rates vary across countries due to differences in risk factors, detection and diagnostic practices, and availability of treatments. The variations are, however, partly caused by the different methodology and quality of data collection [8, 9]. The incidence and mortality of BC has decreased in some registries, possibly reflecting the decreased impact of causative agents [9, 10].

Approximately 75% of patients with BC present with a disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1). They have a high prevalence due to long-term survival in many cases and lower risk of cancer-specific mortality compared to T2-4 tumours [8, 11].

3.2 Aetiology

Tobacco smoking is the most important risk factor for BC, accounting for approximately 50% of cases [8, 12-14] (LE: 3). Tobacco smoke contains aromatic amines and polycyclic aromatic hydrocarbons, which are renally excreted.

Occupational exposure to aromatic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons is the second most important risk factor for BC, accounting for about 10% of all cases. This type of occupational exposure occurs mainly in industrial plants, processing paint, dye, metal and petroleum products [8, 15-17]. In developed industrial settings, these risks have been reduced by work-safety guidelines so that chemical workers no longer have a higher incidence of BC compared to the general population [18].

While family history seems to have little impact [19] and no overt significance of any genetic variation for BC has been shown to date, genetic predisposition has an influence on the incidence of BC via its impact on susceptibility to other risk factors [8, 20, 21].

Although the significance of the amount of fluid intake is uncertain, the chlorination of drinking water and subsequent levels of trihalomethanes are potentially carcinogenic, while exposure to arsenic in drinking water increases risk [8, 11, 22] (LE: 3). The association between personal hair dye use and risk remains uncertain; an increased risk has been suggested in users of permanent hair dyes with an NAT2 slow acetylation phenotype [23, 24]. Other dietary habits seem to have little impact [25].

Exposure to ionizing radiation is connected with increased risk; weak association was also suggested for cyclophosphamide and pioglitazone [8, 11] (LE: 3). Schistosomiasis, a chronic endemic cystitis, based on recurrent infection with a parasitic trematode, is also a cause of BC [8] (LE: 3).

3.3 Pathology

The information presented in text is limited to urothelial carcinoma, unless specified otherwise.

3.4 Summary of evidence

	LE
Worldwide, bladder cancer is the 11 th most commonly diagnosed cancer.	2a
Several risk factors connected with the risk of BC diagnosis have been identified.	3

BC = bladder cancer.

4. STAGING AND CLASSIFICATION SYSTEMS

4.1 Definition of non-muscle-invasive bladder cancer

Papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively, according to the Tumour, Node, Metastasis (TNM) classification system. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis). These tumours can be treated by transurethral resection of the bladder (TURB) and/or intravesical instillations and are therefore grouped under the heading of NMIBC for therapeutic purposes. However, molecular biology techniques and clinical experience have demonstrated the highly malignant potential of CIS and T1 lesions. The terms “NMIBC” and “superficial BC” are therefore suboptimal descriptions.

4.2 Tumour, Node, Metastasis Classification (TNM)

The 2002 TNM classification approved by the Union International Contre le Cancer (UICC) was updated in 2009 (7th Edn.), but with no changes for bladder tumours (Table 4.1) [26].

Table 4.1: 2009 TNM classification of urinary bladder cancer

T - Primary tumour	
TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Ta	Non-invasive papillary carcinoma
Tis	Carcinoma <i>in situ</i> : ‘flat tumour’
T1	Tumour invades subepithelial connective tissue
T2	Tumour invades muscle
T2a	Tumour invades superficial muscle (inner half)
T2b	Tumour invades deep muscle (outer half)
T3	Tumour invades perivesical tissue
T3a	Microscopically
T3b	Macroscopically (extravesical mass)
T4	Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall
T4a	Tumour invades prostate, uterus or vagina
T4b	Tumour invades pelvic wall or abdominal wall
N - Lymph nodes	
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N2	Metastasis in multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or presacral)
N3	Metastasis in common iliac lymph node(s)
M - Distant metastasis	
MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

4.3 Histological grading of non-muscle-invasive bladder urothelial carcinomas


In 2004, the World Health Organization (WHO) and the International Society of Urological Pathology (ISUP) published a new histological classification of urothelial carcinomas which provides a different patient stratification between individual categories compared to the older 1973 WHO classification [27, 28] (Tables 4.2, 4.3, Fig 4.1). Recently an update of the WHO grading classification was published, but the following guidelines are still based on the 2004 WHO classification [28, 29].

Table 4.2: WHO grading in 1973 and in 2004 [27, 28]

<p>1973 WHO grading <i>Urothelial papilloma</i> Grade 1: well differentiated Grade 2: moderately differentiated Grade 3: poorly differentiated</p> <p>2004 WHO grading system [papillary lesions] <i>Urothelial papilloma (completely benign lesion)</i> Papillary urothelial neoplasm of low malignant potential (PUNLMP) Low-grade (LG) papillary urothelial carcinoma High-grade (HG) papillary urothelial carcinoma</p>

The prognostic value of both WHO 1973 and 2004 grading systems has been confirmed. Attempts to demonstrate better prognostic value of one of them, however, have yielded controversial results [30-35]. (LE: 2a). Moreover the WHO 2004 systems have not been fully incorporated into prognostic models yet.

Figure 4.1: Stratification of tumours according to grade in the WHO 1973 and 2004 classifications [30]*



Histologic Spectrum of urothelial carcinoma [UC]

*1973 WHO Grade 1 carcinomas have been reassigned to papillary urothelial neoplasm of low malignant potential (PUNLMP) and low-grade (LG) carcinomas in 2004/2016 WHO classification, and Grade 2 carcinomas to LG and high-grade (HG) carcinomas. All 1973 WHO Grade 3 carcinomas have been reassigned to HG carcinomas (Reproduced with permission from Elsevier).
 PUNLMP = papillary urothelial neoplasm of low malignant potential; WHO = World Health Organization.

4.4 CIS and its classification

Carcinoma *in situ* (CIS) is a flat, high-grade, non-invasive urothelial carcinoma. It can be missed at cystoscopy or be considered as an inflammatory lesion if it is not biopsied. Carcinoma *in situ* is often multifocal and can occur in the bladder, but also in the upper urinary tract, prostatic ducts, and prostatic urethra [36].

Classification of CIS into clinical type [37]:

- Primary: isolated CIS with no previous or concurrent papillary tumours and no previous CIS;
- Secondary: CIS detected during follow-up of patients with a previous tumour that was not CIS;
- Concurrent: CIS in the presence of any other urothelial tumour in the bladder.

Table 4.3: WHO 2004 histological classification for flat lesions

- Urothelial proliferation of uncertain malignant potential (flat lesion without atypia or papillary aspects)
- Reactive atypia (flat lesion with atypia)
- Atypia of unknown significance
- Urothelial dysplasia
- Urothelial CIS is always high-grade

4.5 Inter- and intra-observer variability in staging and grading

There is significant variability among pathologists for diagnosis of CIS, for which agreement is achieved in only 70-78% of cases [38, 39] (LE: 2a). There is also interobserver variability in the classification of stage T1 vs. Ta tumours and tumour grading in both the 1997 and 2004 classifications. The general conformity in staging and grading is between 50% and 60% [34, 38-43] (LE: 2a). The published comparisons have not clearly confirmed that the WHO 2004 classification has better reproducibility than the 1973 classification [31, 34, 44].

4.6 Further promising pathology parameters

Some novel parameters based on pathological investigation of resected tissue have been considered for subclassification and prognostic purposes. In T1 tumours, the depth and extent of invasion into the lamina propria (T1 substaging) can be evaluated. The prognostic value of this evaluation has been demonstrated by some retrospective cohort studies [45-48] (LE: 3); nevertheless, it is not recommended in the WHO classification.

According to a meta-analysis of retrospective trials, the presence of lymphovascular invasion (LVI) in TURB specimens was connected with increased risk of pathological upstaging [49] (LE: 3). Lymphovascular invasion has been reported as an unfavourable prognostic factor in T1 tumours [50] (LE: 3).

Some variants of urothelial carcinoma (micropapillary, plasmocytoid, nested, sarcomatoid, microcystic, squamous and adeno variants of urothelial carcinoma etc.), have a poor prognosis [49, 51-57] (LE: 3).

Molecular markers, particularly FGFR3 mutation status, are promising but need further validation [32, 48, 58-60].

4.7 Summary of evidence – classification

	LE
The depth of invasion (staging) is classified according to the TNM classification.	2a
Papillary tumours confined to the mucosa and invading the lamina propria are classified as stage Ta and T1, respectively. Flat, high-grade tumours that are confined to the mucosa are classified as CIS (Tis).	2a
T1 and CIS have high malignant potential, the term NMIBC is therefore a suboptimal description.	3
For histological classification of NMIBC, the WHO 1973 and 2004 grading systems are used.	2a

CIS (Tis) = carcinoma in situ; NMIBC = non-muscle invasive bladder cancer; TNM = Tumour, Node, Metastasis (classification); WHO = World Health Organization.

4.8 Recommendations for bladder cancer classification

Recommendation	GR
For classification of the depth of tumour invasion (staging) use the 2009 TNM system.	A
For histological classification, use the 1973 and 2004/2016 WHO grading systems.	A
Do not use the term “superficial bladder cancer”.	A
Whenever you use the terminology NMIBC in individual cases, mention the tumour stage and grade.	A

TNM = Tumour, Node, Metastasis (classification); WHO = World Health Organization.

5. DIAGNOSIS

5.1 Patient history

A comprehensive patient history is mandatory.

5.2 Signs and symptoms

Haematuria is the most common finding in NMIBC. CIS might be suspected in patients with “storage” lower urinary tract symptoms.

5.3 Physical examination

Physical examination does not reveal NMIBC.

5.4 Imaging

5.4.1 *Computed tomography urography and intravenous urography*

Computed tomography (CT) urography is used to detect papillary tumours in the urinary tract, which can be seen as filling defects or indicated by hydronephrosis.

Intravenous urography (IVU) can be an alternative if CT is not available [61] (LE: 3), but particularly in muscle-invasive tumours of the bladder and in UTUCs, CT urography gives more information than IVU (including status of lymph nodes and neighbouring organs).

The necessity to perform a baseline CT urography or IVU once a bladder tumour has been detected is questionable due to the low incidence of significant findings obtained [62-64] (LE: 2a). The incidence of UTUCs is low (1.8%), but increases to 7.5% in tumours located in the trigone [63] (LE: 2b). The risk of UTUC during follow up increases in patients with multiple- and high-risk tumours [65] (LE: 3).

5.4.2 *Ultrasound (US)*

Transabdominal US permits characterisation of renal masses, detection of hydronephrosis, and visualisation of intraluminal masses in the bladder [62] (LE: 3). Ultrasound is therefore a useful tool for detection of obstruction in patients with haematuria. However, it cannot exclude the presence of UTUC and cannot replace CT urography.

The diagnosis of CIS cannot be made with imaging methods (CT urography, IVU or US) (LE: 4).

5.5 Urinary cytology

The examination of voided urine or bladder-washing specimens for exfoliated cancer cells has high sensitivity in G3 and high-grade tumours (84%), but low sensitivity in G1 and low-grade tumours (16%) [66]. The sensitivity in CIS detection is 28-100% [67] (LE: 2b). Cytology is useful, particularly as an adjunct to cystoscopy, if G3/CIS malignancy is present. Positive voided urinary cytology can indicate an urothelial tumour anywhere in the urinary tract; negative cytology, however, does not exclude the presence of a tumour.

Cytological interpretation is user-dependent [68]. Evaluation can be hampered by low cellular yield, urinary tract infections, stones, or intravesical instillations, but in experienced hands specificity exceeds 90% [69] (LE: 2b).

Urine collection should respect the recommendation provided in Section 5.10. One cytospin slide from the sample is usually sufficient [70]. In patients with suspect cytology it is reasonable to repeat the investigation [71] (LE: 3).

5.6 Urinary molecular marker tests

Driven by the low sensitivity of urine cytology, numerous urinary tests were developed [69, 72-79]. None of these markers have been accepted for diagnosis or follow-up in routine practice or clinical guidelines. Some urine tests that have been evaluated in several laboratories/centres and with sufficient numbers of patients are listed in Table 5.1.

The following conclusions can be drawn regarding the existing tests:

- Sensitivity is usually higher at the cost of lower specificity, compared to urine cytology [69, 73-82] (LE: 3).
- Benign conditions and BCG influence many urinary marker tests [69, 72-79] (LE: 3).
- Requirements for sensitivity and specificity of a urinary marker test depend on the clinical context of the patient (screening, primary detection, follow up [high risk, low-/intermediate-risk]) [73-76] (LE: 3).
- Patient selection explains the wide range in performance of the markers listed in Table 5.1.
- Unlike other urine tests, false-positive results of UroVysion and microsatellite analysis can be attributed to occult disease and these markers therefore identify patients likely to experience early recurrence [83-87] and possibly progression [88] (LE: 3).

Table 5.1: Summary of main urinary markers

Markers (or test specifications)	Overall sensitivity (%)	Overall specificity (%)	Sensitivity for high-grade tumours (%)	Point-of-care test	LE
UroVysion (FISH)	30-86	63-95	66-70	No	2b
Microsatellite analysis	58-92	73-100	90-92	No	1b
Immunocyt/uCyt +	52-100	63-79	62-92	No	2a
Nuclear matrix Protein 22	47-100	55-98	75-92	Yes	2a
BTA stat	29-83	56-86	62-91	Yes	3
BTA TRAK	53-91	28-83	74-77	No	3
Cytokeratins	12-88	73-95	33-100	No	3

BTA = bladder tumour antigen.

5.7 Potential application of urinary cytology and markers

The following objectives of urinary cytology or molecular tests must be considered.

5.7.1 Screening of the population at risk of bladder cancer

The application of haematuria dipstick, NMP22 or UroVysion in BC screening in high-risk populations has been reported [89, 90]. The low incidence of BC in the general population and the short lead-time impair feasibility and cost-effectiveness [76, 87, 89, 90]. Routine application of screening is not recommended.

5.7.2 Exploration of patients after haematuria or other symptoms suggestive of bladder cancer (primary detection)

It is generally accepted that none of the tests can replace cystoscopy. However, urinary cytology or markers can be used as an adjunct to cystoscopy to detect invisible tumours, particularly CIS. In this setting, sensitivity for high-grade tumours and specificity are particularly important. Urinary cytology is highly specific, but urinary markers lack this high specificity and are not recommended for primary detection.

5.7.3 Surveillance of NMIBC

Research has been carried out into the usefulness of urinary cytology vs. markers in the follow-up of NMIBC [76, 78, 91, 92].

5.7.3.1 Follow-up of high-risk NMIBC

High-risk tumours should be detected early in follow-up, and the percentage of tumours missed should be as low as possible. Therefore, the best surveillance strategy for these patients will continue to include frequent cystoscopy and cytology.

5.7.3.2 Follow-up of low/intermediate-risk NMIBC


To reduce the number of cystoscopy procedures, urinary markers should be able to detect recurrence before the tumours are large and numerous. The limitation of urinary cytology is its low sensitivity for low-grade recurrences. Several urinary markers are better, but still do not detect half of the low-grade tumours identified by cystoscopy [73, 76] (LE: 3).

According to current knowledge, no urinary marker can replace cystoscopy during follow up or help to lower cystoscopic frequency in a routine fashion. One prospective randomised study found that knowledge of positive test results (microsatellite analysis) can improve the quality of follow-up cystoscopy [93] (LE: 1b). It supports the adjunctive role of a non-invasive urine test performed before follow-up cystoscopy [93].

5.8 Cystoscopy

The diagnosis of papillary BC ultimately depends on cystoscopic examination of the bladder and histological evaluation of the resected tissue. CIS is diagnosed by a combination of cystoscopy, urine cytology, and histological evaluation of multiple bladder biopsies [94]. Cystoscopy is initially performed in the office. A flexible instrument with topical intra-urethral anaesthetic lubricant instillation results in better compliance compared to a rigid instrument, especially in men [95].

Figure 5.1: Bladder diagram



- | | |
|----------------------------|------------------------|
| 1 = Trigone | 6 = Anterior wall |
| 2 = Right ureteral orifice | 7 = Posterior wall |
| 3 = Left ureteral orifice | 8 = Dome |
| 4 = Right wall | 9 = Neck |
| 5 = Left wall | 10 = Posterior urethra |

5.9 Summary of evidence – primary assessment of NMIBC

	LE
The diagnosis of BC depends on cystoscopic examination.	1
Urinary cytology has high sensitivity in high-grade tumours including CIS.	2b

BC = bladder cancer; CIS = carcinoma in situ.

5.10 Recommendations for the primary assessment of NMIBC

Recommendation	GR
Patient history should be taken.	A
Renal and bladder US may be used during the initial work-up in patients with haematuria.	C
At the time of the initial diagnosis of NMIBC, CT urography (or IVU) should be performed in selected cases (e.g., tumours located in the trigone, multiple or high-risk tumours).	B
Cystoscopy is recommended in all patients with symptoms suggestive of BC. It cannot be replaced by cytology or by any other non-invasive test.	A
Cystoscopy should describe all macroscopic features of the tumour (site, size, number and appearance) and mucosal abnormalities. A bladder diagram is recommended (Figure 5.1).	C
Voided urine cytology is advocated as an adjunct to cystoscopy to detect high-grade tumour.	C
Cytology should be performed on fresh urine with adequate fixation. Morning urine is not suitable because of the frequent presence of cytolysis.	C

BC = bladder cancer; CT = computed tomography; IVU = intravenous urography; NMIBC = non-muscle invasive bladder cancer; US = ultrasound.

5.11 Transurethral resection of Ta, T1 bladder tumours

5.11.1 Strategy of the procedure

The goal of TURB in Ta, T1 BC is to make the correct diagnosis and completely remove all visible lesions. It is a crucial procedure in the diagnosis and treatment of BC. TURB should be performed systematically in individual

steps (see Section 5.16). The strategy of resection depends on the size of the lesion (see Section 5.16).

Separate resection of larger tumours provides good information about the vertical and horizontal extent of the tumour and helps to improve completeness of resection [96, 97] (LE: 3).

A complete and correct TURB is essential to achieve a good prognosis [98]. It has been confirmed that the absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease, early recurrence and tumour understaging [97, 99] (LE: 2b). It has been shown that surgical experience can improve TURB results, which supports the role of teaching programmes [100].

5.11.2 **Office-based fulguration**

In patients with a history of small, Ta LG/G1 tumours, fulguration of small papillary recurrences on an outpatient basis can reduce the therapeutic burden and can be a treatment option [101, 102] (LE: 3). There are no prospective comparative studies assessing the oncological outcomes.

5.11.3 **New resection techniques**

Compared to monopolar resection, the bipolar electrocautery system has been introduced to reduce the risk of complications (e.g., bladder perforation due to obturator nerve stimulation) and produce better specimens for the pathologist [103] (LE: 3). Currently, the results remain controversial [104-106].

5.11.4 **Bladder and prostatic urethral biopsies**

Carcinoma *in situ* can present as a velvet-like, reddish area indistinguishable from inflammation, or it may not be visible at all. For this reason, the strategy of taking biopsies from abnormal urothelium and biopsies from normal-looking mucosa (random/mapping biopsies) is recommended (see Section 5.16). The indication for random biopsies reflects the fact, that the likelihood of detecting CIS, especially in low-risk tumours, is extremely low (< 2%) [107] (LE: 2a). The risk increases in patients with high-risk tumours and with positive cytology [108].

If equipment is available, photodynamic diagnosis (PDD) is a useful tool to target the biopsy (see Section 5.12.1).

Involvement of the prostatic urethra and ducts in men with NMIBC has been reported. Palou *et al.* [109] showed that in 128 men with T1G3 BC, the incidence of CIS in the prostatic urethra was 11.7% (LE: 2b). The risk of prostatic urethra- or duct involvement is higher if the tumour is located on the trigone or bladder neck, in the presence of bladder CIS and multiple tumours [110] (LE: 3). Based on this observation, a biopsy from the prostatic urethra is necessary in some cases (see recommendation in Section 5.16) [109, 111].

5.12 **New methods of tumour visualisation**

As a standard procedure, cystoscopy and TURB are performed using white light. However, the use of white light can lead to missing lesions that are present but not visible, which is why new technologies are being developed.

5.12.1 **Photodynamic diagnosis (fluorescence cystoscopy)**

Photodynamic diagnosis (PDD) is performed using violet light after intravesical instillation of 5-aminolaevulinic acid (ALA) or hexaminolaevulinic acid (HAL). It has been confirmed that fluorescence-guided biopsy and resection are more sensitive than conventional procedures for the detection of malignant tumours, particularly for CIS [112, 113] (LE: 2a). In a systematic review and meta-analysis, PDD had higher sensitivity than white-light endoscopy in the pooled estimates for analyses at both the patient-level (92% vs.71%) and biopsy-level (93% vs.65%) [113]. A prospective randomised trial did not confirm a higher detection rate in patients with known positive cytology before TURB [114].

Photodynamic diagnosis had lower specificity than white-light endoscopy (63% vs. 81%) [113]. False-positivity can be induced by inflammation or recent TURB and during the first 3 months after BCG instillation [115, 116] (LE: 3). Prospective randomised studies evaluating the impact of ALA fluorescence-guided (FC) TURB on disease-recurrence rate provided controversial results [113, 117, 118].

The beneficial effect of HAL FC on recurrence rate in patients with TURB was confirmed by a multicentre, prospective, randomised trial and by a raw-data based meta-analysis of controlled trials. A meta-analysis reported in HAL arms an increase in detection of tumour lesions across all risk groups and an absolute reduction of < 10% in recurrence rates within 12 months [119] (LE: 1a). The beneficial effect of HAL FC on recurrence rate in patients with TURB and early intravesical instillation of chemotherapy was not confirmed by two prospective randomised trials [120, 121]. The value of FC for improvement of outcome in relation to progression rate, survival and clinical management remains to be demonstrated.

5.12.2 **Narrow-band imaging**

In narrow-band imaging (NBI), the contrast between normal urothelium and hyper-vascular cancer tissue is enhanced. Initial studies have demonstrated improved cancer detection by NBI-guided biopsies and resection [122, 123] (LE: 3). The suggested reduction of recurrence rate if NBI is used during TURB has not yet been fully confirmed [124].

5.13 **Second resection**

The significant risk of residual tumour after initial TURB of Ta, T1 lesions has been demonstrated [98] (LE: 2a). Persistent disease after resection of T1 tumours has been observed in 33-55% of patients, and after resection of TaG3 tumour in 41.4% [125-129]. Moreover, the tumour is often understaged by initial resection. The likelihood that muscle-invasive disease is detected by second resection of initially T1 tumour ranges from 4-25%, and it increases to 45% if there was no muscle in the initial resection [114]. This risk increased to 50% in some radical cystectomy (RC) series, although these studies only enrolled selected patients [130-132] (LE: 2a). Treatment of a Ta, T1 high-grade tumour and a T2 tumour is completely different; correct staging is therefore important.

It has been demonstrated that a second TURB can increase recurrence-free survival [125, 126] (LE: 2a), improve outcomes after BCG treatment [133] (LE: 3) and provide prognostic information [130, 134] (LE: 3). Based on these arguments, a second TURB is recommended in selected cases (see Section 5.16).

5.14 **Pathology report**

Pathological investigation of the specimen(s) obtained by TURB and biopsies is an essential step in the diagnosis and treatment decision-making process for BC. Close co-operation between urologists and pathologists is recommended. A high quality of resected and submitted tissue is essential for correct pathological assessment. The presence of sufficient muscle is necessary for the correct assignment of T category. To obtain all required information, the specimen collection, handling and evaluation should respect the recommendations provided below (see Section 5.16) [135].

5.15 **Summary of evidence - TURB and pathology report**

	LE
TURB followed by pathology investigation of the obtained specimen(s) is an essential step in the treatment of NMIBC.	1
The absence of detrusor muscle in the specimen is associated with a significantly higher risk of residual disease and tumour understaging.	2b
In patients with a history of small, Ta LG/G1 tumours, fulguration of small papillary recurrences on an outpatient basis is feasible and safe.	3
A second TURB can detect residual tumours and tumour understaging, increase recurrence-free survival, improve outcomes after BCG treatment and provide prognostic information.	

BCG = bacillus Calmette-Guérin; TURB = transurethral resection of the bladder.

5.16 **Recommendations for TURB and/or biopsies and pathology report**

Recommendation	GR
In patients suspected of harbouring bladder cancer TURB followed by pathology investigation of the obtained specimen(s) is recommended as a diagnostic procedure and initial treatment step.	A
Perform TURB systematically in individual steps: <ul style="list-style-type: none"> • bimanual palpation under anaesthesia; • insertion of the resectoscope, under visual control with inspection of the whole urethra; • inspection of the whole urothelial lining of the bladder; • biopsy from prostatic urethra (if indicated); • cold-cup bladder biopsies (if indicated); • resection of the tumour; • surgical report formulation; • precise description of the specimen for pathology evaluation. 	C
Performance of individual steps:	
Perform resection in one piece for small papillary tumours (< 1 cm), including part from the underlying bladder wall.	B
Perform resection in fractions including the exophytic part of the tumour, the underlying bladder wall with the detrusor muscle, and the edges of the resection area for tumours > 1 cm in diameter.	B

Avoid cauterisation as much as possible during TURB to avoid tissue deterioration.	C
Take biopsies from abnormal-looking urothelium. Biopsies from normal-looking mucosa (trigone, bladder dome, and right, left, anterior and posterior bladder walls) are recommended when cytology is positive or when high-risk exophytic tumour is expected (non-papillary appearance). If equipment is available, use PDD-guided biopsies.	B
Take biopsy of the prostatic urethra in cases of bladder neck tumour, when bladder CIS is present or suspected, when there is positive cytology without evidence of tumour in the bladder, or when abnormalities of the prostatic urethra are visible. If biopsy is not performed during the initial procedure, it should be completed at the time of the second resection.	C
Take the biopsy from abnormal areas in the prostatic urethra and from the precollicular area (between 5 and 7 o'clock position) using a resection loop. In primary non-muscle-invasive tumours when stromal invasion is not suspected, cold-cup biopsy with forceps can be used.	C
Refer the specimens from different biopsies and resection fractions to the pathologist in separate containers and label them separately.	C
TURB protocol must describe tumour appearance, all steps of the procedure, as well as the extent and completeness of resection.	C
In patients with positive cytology, but negative cystoscopy, exclude a UTUC, CIS in the bladder (random biopsies or PDD-guided biopsies) and tumour in prostatic urethra (prostatic urethra biopsy).	C
Perform a second TURB in the following situations: <ul style="list-style-type: none"> • after incomplete initial TURB; • if there is no muscle in the specimen after initial resection, with exception of TaG1 tumours and primary CIS; • in all T1 tumours; • in all HG/G3 tumours, except primary CIS. 	A
If indicated, perform a second TURB within 2-6 weeks after initial resection. It should include the resection of primary tumour site.	C
Pathological report	
The pathological report should specify tumour location, tumour grade, depth of tumour invasion, presence of CIS, and whether the detrusor muscle is present in the specimen.	A
The pathological report should specify the presence of LVI or unusual (variant) histology.	C
In difficult cases, consider an additional review by an experienced genitourinary pathologist.	B

CIS = carcinoma in situ; LVI = lymphovascular invasion; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder; UTUC = upper tract urothelial carcinoma.

6. PREDICTING DISEASE RECURRENCE AND PROGRESSION

6.1 Ta, T1 tumours

In order to predict separately the short- and long-term risks of disease recurrence and progression in individual patients, the EORTC Genito-Urinary Cancer Group has developed a scoring system and risk tables [136]. The basis for these tables are individual patient data from 2,596 patients diagnosed with Ta, T1 tumours, who were randomised into seven EORTC trials. Patients with CIS alone were not included. Seventy-eight percent of patients received intravesical treatment, mostly chemotherapy. However, they did not undergo a second TURB or receive maintenance BCG.

The scoring system is based on the six most significant clinical and pathological factors which are shown in Table 6.1. It also illustrates the weights applied to various factors for calculating the total scores for recurrence and progression. Table 6.2 shows the total scores stratified, as in the original article [136], into four categories that reflect various probabilities of recurrence and progression at 1 and 5 years (LE: 2a).

Table 6.1: Weighting used to calculate disease recurrence and progression scores

Factor	Recurrence	Progression
Number of tumours		
Single	0	0
2-7	3	3
≥ 8	6	3
Tumour diameter		
< 3 cm	0	0
≥ 3	3	3
Prior recurrence rate		
Primary	0	0
≤ 1 recurrence/year	2	2
> 1 recurrence/year	4	2
Category		
Ta	0	0
T1	1	4
Concurrent CIS		
No	0	0
Yes	1	6
Grade		
G1	0	0
G2	1	0
G3	2	5
Total Score	0-17	0-23

Table 6.2: Probability of recurrence and disease progression according to total score

Recurrence score	Probability of recurrence at 1 year		Probability of recurrence at 5 years	
	%	(95% CI)	%	(95% CI)
0	15	(10-19)	31	(24-37)
1-4	24	(21-26)	46	(42-49)
5-9	38	(35-41)	62	(58-65)
10-17	61	(55-67)	78	(73-84)

Progression score	Probability of progression at 1 year		Probability of progression at 5 years	
	%	(95% CI)	%	(95% CI)
0	0.2	(0-0.7)	0.8	(0-1.7)
2-6	1	(0.4-1.6)	6	(5-8)
7-13	5	(4-7)	17	(14-20)
14-23	17	(10-24)	45	(35-55)

NB: Electronic calculators for Tables 6.1 and 6.2, which have been updated for the iPhone, iPad and Android phones and tablets, are available at <http://www.eortc.be/tools/bladdercalculator/>.

A scoring model for BCG-treated patients that predicts the short- and long-term risks of recurrence and progression has been published by the Club Urológico Español de Tratamiento Oncológico (CUETO) (Spanish Urological Oncology Group). It is based on an analysis of 1,062 patients from four CUETO trials that compared different intravesical BCG treatments. Patients received 12 instillations over 5-6 months. No immediate post-operative instillation or second TURB was performed in these patients. The scoring system is based on the evaluation of seven prognostic factors:

- sex;
- age;
- prior recurrence status;
- number of tumours;
- T category;
- associated CIS;
- tumour grade.

Using these tables, the calculated risk of recurrence is lower than that obtained by the EORTC tables. For progression, probability is lower only in high-risk patients [137] (LE: 2a). The lower risks in the CUETO tables may be attributed to using BCG, which is a more effective instillation therapy. The CUETO risk calculator is available at: <http://www.aeu.es/Cueto.html>.

The prognostic value of the EORTC scoring system has been confirmed by data from the CUETO patients treated with BCG and by long-term follow up in an independent patient population [138, 139] (LE: 2a).

In 1,812 intermediate- and high-risk patients without CIS treated with 1 to 3 years of maintenance BCG, the EORTC found that the prior disease-recurrence rate and number of tumours were the most important prognostic factors for disease recurrence, stage and grade were the most important prognostic factors for disease progression and disease-specific survival, while age and grade were the most important prognostic factors for overall survival (OS). T1G3 patients do poorly, with 1- and 5-year disease-progression rates of 11.4% and 19.8%, respectively. Using these data the new EORTC risk tables for BCG treated patients were designed [140] (LE: 2a).

Further prognostic factors have been described in selected patient populations:

- In T1G3 tumours important prognostic factors were female sex and CIS in the prostatic urethra in patients treated with an induction course of BCG, and age, tumour size and concurrent CIS in BCG-treated patients (62% with induction course only) [109] [141] (LE: 2b).
- Attention must be given to patients with T1G3 tumours in bladder (pseudo) diverticulum because of an absence of muscle layer in the diverticular wall [142] (LE: 3).
- In patients with high-risk disease, the tumour stage at the time of the 2nd TURB is an unfavourable prognostic factor [130, 134] (LE: 3)
- In patients with T1G2 tumours treated with TURB, recurrence at 3 months was the most important predictor of progression [143] (LE: 2b).
- The prognostic value of pathological factors has been discussed elsewhere (see Section 4.6). More research is needed to determine the role of molecular markers in improving the predictive accuracy of currently available risk tables [138, 144].

6.2 Carcinoma *in situ*

Without any treatment, approximately 54% of patients with CIS progress to muscle-invasive disease [145] (LE: 3). Unfortunately, there are no reliable prognostic factors that can be used to predict the course of the disease. Publications are based on retrospective analyses of small series of patients and conclusions are not homogeneous. Some studies have reported a worse prognosis in concurrent CIS and T1 tumours compared to primary CIS [146, 147], in extended CIS [148] and in CIS in the prostatic urethra [109] (LE: 3).

The response to intravesical treatment with BCG or chemotherapy is an important prognostic factor for subsequent progression and death caused by BC [137-139, 143]. Approximately 10-20% of complete responders eventually progress to muscle-invasive disease, compared with 66% of non-responders [149, 150] (LE: 2a).

6.3 Patient stratification into risk groups

To facilitate treatment recommendations it is important to categorise patients into risk groups. Based on available prognostic factors and in particular data from the EORTC risk tables, the Guidelines Panel recommends stratification of patients into three risk groups. Table 6.3 provides a definition of these risk groups, which takes into account the EORTC risk tables' probabilities of recurrence and especially progression.

Table 6.3: Risk group stratification

Risk group stratification	Characteristics
Low-risk tumours	Primary, solitary, Ta, G1* (PUNLMP, LG), < 3 cm, no CIS
Intermediate-risk tumours	All tumours not defined in the two adjacent categories (between the category of low- and high-risk).
High-risk tumours	Any of the following: <ul style="list-style-type: none"> • T1 tumour • G3** (HG) tumour • CIS • Multiple and recurrent and large (> 3 cm) Ta, G1G2 tumours (all conditions must be presented in this point)*

Substratification of high-risk tumours for clinical purposes is addressed in Table 7.2.

*low grade is a mixture of G1 and G2

** high grade is a mixture of some G2 and all G3 (see Figure 4.1)

CIS = carcinoma in situ; HG = high-grade; LG = low-grade; PUNLUMP = Papillary urothelial neoplasm of low malignant potential.

6.4 Summary of evidence - stratification of NMIBC

	LE
The EORTC scoring system and risk tables predict the short- and long-term risks of disease recurrence and progression in individual patients with NMIBC.	2a
In patients treated with BCG, the CUETO scoring model predicts the short- and long-term risks of disease recurrence and progression.	2a
In patients receiving BCG maintenance, prior recurrence rate and number of tumours are the most important prognostic factors for disease recurrence.	2a
Stage and grade are the most important prognostic factors for disease progression and disease specific survival.	
Patient age and grade are the most important prognostic factors for OS.	

BCG = bacillus Calmette-Guérin; CUETO = Club Urológico Español de Tratamiento Oncológico; EORTC = European Organization for Research and Treatment of Cancer; OS = overall survival.

6.5 Recommendations for stratification of NMIBC

Recommendation	GR
Stratify patients into three risk groups according to Table 6.3.	B
Apply EORTC risk tables and calculator for individual prediction of the risk of tumour recurrence and progression in different intervals after TURB.	B
For individual prediction of the risk of tumour recurrence and progression in patients treated with BCG use the CUETO risk tables and the new EORTC risk tables.	B

BCG = bacillus Calmette-Guérin; CUETO = Club Urológico Español de Tratamiento Oncológico; EORTC = European Organization for Research and Treatment of Cancer; TURB = transurethral resection of the bladder.

7. DISEASE MANAGEMENT

7.1 Counselling of smoking cessation

It has been confirmed that smoking increases the risk of tumour recurrence and progression [151, 152] (LE: 3). While it is still controversial whether smoking cessation in bladder cancer will favourably influence the outcome of BC treatment, patients should be counselled to stop smoking due to the general risks connected with tobacco smoking [153-156] (LE: 3).

7.2 Adjuvant treatment

7.2.1 Intravesical chemotherapy

Although TURB by itself can eradicate a Ta, T1 tumour completely, these tumours commonly recur and can progress to MIBC. The high variability in the 3-month recurrence rate indicates that the TURB was incomplete or provokes recurrences in a high percentage of patients [98]. It is therefore necessary to consider adjuvant therapy in all patients.

7.2.1.1 A single, immediate, post-operative intravesical instillation of chemotherapy

Immediate single instillation (SI) has been shown to act by destroying circulating tumour cells after TURB, and by an ablative effect (chemoresection) on residual tumour cells at the resection site and on small overlooked tumours [157-160] (LE: 3).

Four large meta-analyses comprising 1,476 to 3,103 patients have consistently shown that after TURB, SI significantly reduces the recurrence rate compared to TURB alone [4, 161-163] (LE: 1a). In the most recent systematic review and individual patient data meta-analysis of 2,278 eligible patients [4], SI reduced the 5-year recurrence rate by 14%, from 59% to 45%. The number to treat (NNT) to prevent one recurrence within 5 years was 7 eligible patients. Only patients with a prior recurrence rate of less than or equal to one recurrence per year and those with an EORTC recurrence score < 5 benefited from SI. In patients with an EORTC recurrence score ≥ 5 and/or patients with a prior recurrence rate of > 1 recurrence per year, SI was not effective as a single adjuvant treatment in these two subgroups of patients. Mitomycin C (MMC), epirubicin, and pirarubicin have all shown a beneficial effect [4]. No randomised comparisons of individual drugs have been conducted [4, 161-163] (LE: 1a).

Prevention of tumour cell implantation should be initiated within the first few hours after TURB. After that, tumour cells are firmly implanted and are covered by extracellular matrix [157, 164-166] (LE: 3). In all SI studies, the instillation was administered within 24 hours. To maximize the efficacy of SI, one should devise flexible practices that allow the instillation to be given as soon as possible after TURB, preferably within the first 2 hours in the recovery room or even in the operating theatre.

As severe complications have been reported in patients with drug extravasation [167, 168] safety measures should be maintained (see Section 7.5).

7.2.1.2 Additional adjuvant intravesical chemotherapy instillations

The need for further adjuvant intravesical therapy depends on prognosis. In low-risk patients (Tables 6.1, 6.2 and 6.3), a SI reduces the risk of recurrence and is considered to be the standard and complete treatment [161] (LE: 1a). For other patients, however, a SI remains an incomplete treatment because of the considerable likelihood of recurrence and/or progression (Tables 6.1, 6.2 and 6.3). The individual patient data meta-analysis also showed that a SI reduced recurrences in intermediate-risk patients with an EORTC recurrence score < 5, none of whom received further treatment prior to recurrence. There is evidence from several studies in intermediate-risk patients that SI might have an impact on recurrence even when further adjuvant instillations are given, however they do not take into account the EORTC recurrence score [169-171] (LE: 2a). In one study [172], further chemotherapy instillations after SI improved recurrence-free survival in intermediate-risk patients (LE: 2a). Conversely, a sufficient number of delayed repeat chemotherapy instillations without SI can also reduce recurrences [169, 171].

A large meta-analysis of 3,703 patients from 11 randomised trials showed a highly significant 44% reduction in the odds of recurrence at one year in favour of chemotherapy over TURB alone [173]. This corresponds to an absolute difference of 13-14% in the number of patients with recurrence. Contrary to these findings, two meta-analyses have demonstrated that BCG therapy may reduce the risk of tumour progression [174, 175] (LE: 1a) (see Section 7.2.2.1). Moreover, BCG maintenance therapy appears to be significantly better in preventing recurrences than chemotherapy [176-178] (see Section 7.2.2) (LE: 1a). However, BCG causes significantly more side effects than does chemotherapy [178] (LE: 1a).

The length and frequency of chemotherapy instillations is still controversial. A systematic review of RCTs, comparing different schedules of intravesical chemotherapy instillations, concluded that the ideal duration and intensity of the schedule remains undefined because of conflicting data [171]. The available evidence does not support treatment longer than one year (LE: 3).

7.2.1.3 Options for improving efficacy of intravesical chemotherapy

7.2.1.3.1 Adjustment of pH, duration of instillation, and drug concentration

One RCT using MMC has demonstrated that adapting urinary pH, decreasing urinary excretion, and buffering the intravesical solution reduced the recurrence rate [179] (LE: 1b). Another trial reported that a 1-hour instillation of MMC was more effective than 30 minutes instillation, but no efficacy comparisons are available for 1- and 2-hour instillations [180] (LE: 3). Another RCT using epirubicin has documented that concentration is more important than treatment duration [181] (LE: 1b). In view of these data, instructions are provided (see Section 7.5).

7.2.1.3.2 Microwave-induced hyperthermia and electromotive drug administration (EMDA)

Promising data have been presented on enhancing the efficacy of MMC using microwave-induced hyperthermia or the efficacy of MMC using electromotive drug administration (EMDA) in patients with high-risk tumours. The current evidence, however, is limited [182-184] and both treatment modalities are considered to be experimental (LE: 2b).

7.2.1.4 Summary of evidence - intravesical chemotherapy

	LE
In patients with NMIBC and prior low recurrence rate (less than or equal to one recurrence per year) and in those with an EORTC recurrence score < 5, SI significantly reduces the recurrence rate compared to TURB alone.	1a
In intermediate-risk patients, SI might have an impact on recurrence even when further adjuvant instillations are given.	3
Further chemotherapy instillations after SI improve recurrence-free survival in intermediate-risk patients.	2a

EORTC = European Organization for Research and Treatment of Cancer; SI = single instillation;

TURB = transurethral resection of the bladder.

7.2.2 Intravesical bacillus Calmette-Guérin (BCG) immunotherapy

7.2.2.1 Efficacy of BCG

Five meta-analyses have confirmed that BCG after TURB is superior to TURB alone or TURB + chemotherapy for preventing the recurrence of NMIBC [176, 185-188] (LE: 1a). Three recent RCTs of intermediate- and high-risk tumours have compared BCG with epirubicin + interferon [189], MMC [190], or epirubicin alone [177] and have confirmed the superiority of BCG for prevention of tumour recurrence (LE: 1a). The effect is long-lasting [177, 190] and was also observed in a separate analysis of patients with intermediate-risk tumours [177].

One meta-analysis [176] has evaluated the individual data from 2,820 patients enrolled in nine RCTs that have compared MMC vs. BCG. In the trials with BCG maintenance, there was a 32% reduction in the risk of recurrence for BCG compared to MMC, but a 28% increase in the risk of recurrence for patients treated with BCG in the trials without BCG maintenance.

Two meta-analyses have demonstrated that BCG therapy prevents, or at least delays, the risk of tumour progression [174, 175] (LE: 1a). A meta-analysis carried out by the EORTC-GUCG has evaluated data from 4,863 patients enrolled in 24 RCTs. Five different BCG strains were used, and in 20 of the trials, some form of BCG maintenance was used. Based on a median follow-up of 2.5 years, in 260 out of 2,658 patients (9.8%) treated with BCG, tumours progressed compared to 304 out of 2,205 (13.8%) in the control groups (TURB alone, TURB + intravesical chemotherapy, or TURB + other immunotherapy). This shows a reduction of 27% in the odds of progression with BCG maintenance treatment. The size of the reduction was similar in patients with Ta, T1 papillary tumours and in those with CIS [175]. A recent RCT with long-term observation has demonstrated significantly fewer distant metastases and better overall- and disease-specific survival in patients treated with BCG compared to epirubicin [177] (LE: 1b). On the contrary, a meta-analysis of individual patient data was not able to confirm any statistically significant difference between MMC and BCG for progression, survival and cause of death [176].

The conflicting results in the outcomes of these studies can be explained by different patient characteristics, duration of follow-up, methodology and statistical power. However, most studies showed a reduction in the risk of progression in high- and intermediate-risk tumours if BCG was applied including a maintenance schedule.

Two other meta-analyses have suggested a possible bias in favour of BCG arising from the inclusion of patients previously treated with intravesical chemotherapy [191]. In the most recent meta-analysis, however, BCG maintenance was more effective than MMC, both in patients previously treated and not previously treated with chemotherapy [176] (LE: 1a). It was demonstrated that BCG was less effective in patients > 70 years of age, but it was still more effective than epirubicin [192] (LE: 1a).

7.2.2.2 BCG strain

The EORTC meta-analysis suggested no large differences in efficacy between various BCG strains [175]. Recently published smaller studies without maintenance demonstrated some differences between strains. This clearly needs further evaluation in prospective trials [193, 194] (LE: 2a).

7.2.2.3 BCG toxicity

BCG intravesical treatment is associated with more side effects compared to intravesical chemotherapy [175]

(LE: 1a). However, serious side effects are encountered in < 5% of patients and can be treated effectively in almost all cases [195] (LE: 1b). It has been shown that a maintenance schedule is not associated with an increased risk of side effects compared to an induction course [195]. Side effects requiring treatment stoppage were seen more often in the first year of therapy [196].

Major complications can appear after systemic absorption of the drug. Thus, contraindications of BCG intravesical instillation should be respected (see Section 7.5).

The presence of leukocyturia, non-visible haematuria or asymptomatic bacteriuria is not a contraindication for BCG application, and antibiotic prophylaxis is not necessary in these cases [197, 198] (LE: 3).

BCG should be used with caution (relative contraindication) in immunocompromised patients (immunosuppression, human immunodeficiency virus [HIV] infection) [199], although some small studies have shown similar efficacy and no increase in complications compared to non-immunocompromised patients. The role of prophylactic anti-tuberculosis medication in these patients remains unclear [200-202] (LE: 3).

The management of side effects after BCG should reflect their type and grade according to the recommendations provided by the International Bladder Cancer Group (IBCG) and by a Spanish group [203, 204] (Table 7.1).

Table 7.1: Management options for side effects associated with intravesical BCG [204-207]

Management options for local side effects (modified from IBCG group)	
Symptoms of cystitis	Phenazopyridine, propantheline bromide, or NSAIDs
	If symptoms improve within a few days: continue instillations
	If symptoms persist or worsen: <ul style="list-style-type: none"> a. Postpone the instillation b. Perform a urine culture c. Start empirical antibiotic treatment
	If symptoms persist even with antibiotic treatment: <ul style="list-style-type: none"> d. With positive culture: antibiotic treatment according to sensitivity e. With negative culture: quinolones and potentially analgesic anti-inflammatory instillations once daily for 5 days (repeat cycle if necessary) [205].
	If symptoms persist: anti-tuberculosis drugs + corticosteroids.
	If no response to treatment and/or contracted bladder: radical cystectomy.
Haematuria	Perform urine culture to exclude haemorrhagic cystitis, if other symptoms present.
	If haematuria persists, perform cystoscopy to evaluate presence of bladder tumour.
Symptomatic granulomatous prostatitis	Symptoms rarely present: perform urine culture.
	Quinolones.
	If quinolones are not effective: isoniazid (300 mg/day) and rifampicin (600 mg/day) for 3 months.
	Cessation of intravesical therapy.
Epididymo-orchitis [206]	Perform urine culture and administer quinolones.
	Cessation of intravesical therapy.
	Orchidectomy if abscess or no response to treatment.
Management options for systemic side effects	
General malaise, fever	Generally resolve within 48 hours, with or without antipyretics.
Arthralgia and/or arthritis	Rare complication and considered autoimmune reaction.
	Arthralgia: treatment with NSAIDs.
	Arthritis: NSAIDs.
	If no/partial response, proceed to corticosteroids, high-dose quinolones or anti-tuberculosis drugs [207].
Persistent high-grade fever (> 38.5°C for > 48 h)	Permanent discontinuation of BCG instillations.
	Immediate evaluation: urine culture, blood tests, chest X-ray.
	Prompt treatment with > two antimicrobial agents while diagnostic evaluation is conducted.
	Consultation with an infectious diseases specialist.

BCG sepsis	Prevention: initiate BCG at least 2 weeks post-TURB (if no signs and symptoms of haematuria).
	Cessation of BCG.
	For severe infection: <ul style="list-style-type: none"> • High-dose quinolones or isoniazid, rifampicin and ethambutol 1.2 g daily for 6 months. • Early, high-dose corticosteroids as long as symptoms persist. Consider an empirical non-specific antibiotic to cover Gram-negative bacteria and/or <i>Enterococcus</i> .
Allergic reactions	Antihistamines and anti-inflammatory agents.
	Consider high-dose quinolones or isoniazid and rifampicin for persistent symptoms.
	Delay therapy until reactions resolve.

BCG = *bacillus Calmette-Guérin*; IBCG = *International Bladder Cancer Group*; NSAID = *non-steroidal antiinflammatory drug*; TURBT = *transurethral resection of bladder tumour*.

7.2.2.4 Optimal BCG schedule

Induction BCG instillations are given according to the empirical 6-weekly schedule introduced by Morales [208]. For optimal efficacy, BCG must be given in a maintenance schedule [174-176, 188] (LE: 1a). Many different maintenance schedules have been used, ranging from a total of 10 instillations given in 18 weeks to 27 over 3 years [209]. The EORTC meta-analysis was unable to determine which BCG maintenance schedule was the most effective [175]. In their meta-analysis, Böhle *et al.* concluded that at least one year of maintenance BCG is required to obtain superiority of BCG over MMC for prevention of recurrence or progression [174] (LE: 1a).

The optimal number of induction instillations and optimal frequency and duration of maintenance instillations is not fully known. Moreover, it can be different in each individual patient [210]. In a RCT of 1,355 patients, the EORTC has shown that when BCG is given at full dose, 3 years' maintenance (three-weekly instillations 3, 6, 12, 18, 24, 30 and 36 months) reduces the recurrence rate compared to one year in high- but not in intermediate-risk patients. There were no differences in progression or OS. In the 3-year arm, however, 36.1% of patients did not complete the 3-years schedule [211] (LE: 1b). In a RCT of 397 patients CUETO suggested that in high-risk tumours, the maintenance schedule with only 1 instillation every 3 months for 3 years may be suboptimal [212] (LE: 1b).

7.2.2.5 Optimal dose of BCG

To reduce BCG toxicity, instillation of a reduced dose was proposed. However, it has been suggested that a full dose of BCG is more effective in multifocal tumours [213, 214] (LE: 1b). The CUETO study compared one-third dose to full-dose BCG and found no overall difference in efficacy. One-third of the standard dose of BCG might be the minimum effective dose for intermediate-risk tumours. A further reduction to one-sixth dose resulted in a decrease in efficacy with no decrease in toxicity [215] (LE: 1b).

The EORTC did not find any difference in toxicity between one-third and full-dose BCG, but one-third dose BCG was associated with a higher recurrence rate, especially when it was given only for one year [196, 211] (LE: 1b). Moreover, the routine application is complicated by potential technical difficulties in preparing the reduced dose reliably.

7.2.2.6 Indications for BCG

Although BCG is a very effective treatment, there is a consensus that not all patients with NMIBC should be treated with BCG due to the risk of toxicity. Ultimately, the choice of treatment depends upon the patient's risk (Table 6.2). The recommendation for individual risk groups is provided in Section 7.5.

A statement by the panel on BCG shortage can be accessed on line: <https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/?type=appendices-publications>.

7.2.2.7 Summary of evidence - BCG treatment

	LE
In patients with intermediate- and high-risk tumours, intravesical BCG after TURB reduces the risk of tumour recurrence, it is more effective than TURB alone or TURB + intravesical chemotherapy.	1a
For optimal efficacy, BCG must be given in a maintenance schedule.	1a
Three-year maintenance is more effective than one year in patients with high-risk tumours, but not in patients with intermediate-risk tumours.	1a

BCG = *bacillus Calmette-Guérin*; TURB = *transurethral resection of the bladder*.

7.2.3 **Combination therapy**

In one RCT, a combination of MMC and BCG reduced recurrences but was more toxic compared to BCG monotherapy. Using similar BCG schedules in both groups, each BCG instillation in the combination group was preceded a day before by one MMC instillation [216]. Another RCT demonstrated that in frequently recurrent NMIBC significantly higher efficacy of weekly MMC followed by monthly BCG in reduction of the recurrence rate when compared to BCG and interferon [217]. In the RCT using MMC with EMDA, a combination of BCG and MMC with EMDA showed an improved recurrence-free interval and reduced progression rate compared to BCG monotherapy [183].

7.2.4 **Specific aspects of treatment of CIS**

7.2.4.1 *Treatment strategy*

The detection of concurrent CIS increases the risk of recurrence and progression of Ta, T1 tumours [136, 137], further treatment according to the criteria summarised in Sections 7.2.1, 7.2.2, 7.3 and 7.4 is mandatory.

CIS cannot be cured by an endoscopic procedure alone. Histological diagnosis of CIS must be followed by further treatment, either intravesical BCG instillations or radical cystectomy (RC) (LE: 4). Tumour-specific survival rates after immediate RC for CIS are excellent, but as many as 40-50% of patients might be over-treated [145] (LE: 3).

7.2.4.2 *Cohort studies on intravesical BCG or chemotherapy*

In retrospective evaluations of patients with CIS, a complete response rate of 48% was achieved with intravesical chemotherapy and 72-93% with BCG [145-148, 218] (LE: 2a). Up to 50% of complete responders might eventually show recurrence with a risk of invasion and/or extravesical recurrence [148, 209, 218, 219] (LE: 3).

7.2.4.3 *Prospective randomised trials on intravesical BCG or chemotherapy*

Unfortunately, there have been few randomised trials in patients with CIS alone. A meta-analysis of clinical trials comparing intravesical BCG to intravesical chemotherapy in patients with CIS has shown a significantly increased response rate after BCG and a reduction of 59% in the odds of treatment failure with BCG [220] (LE: 1a).

In an EORTC-GUCG meta-analysis of tumour progression (a subgroup of 403 patients with CIS), BCG reduced the risk of progression by 35% as compared to intravesical chemotherapy or different immunotherapy [175] (LE: 1b). The combination of BCG and MMC was not superior to BCG alone [221]. In summary, compared to chemotherapy, BCG treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression (LE: 1b).

7.2.4.4 *Treatment of CIS in prostatic urethra and upper urinary tract*

Patients with CIS are at high risk of extravesical involvement in the UUT and in the prostatic urethra. Solsona *et al.* found that 63% of 138 patients with CIS developed extravesical involvement initially or during follow-up [222]. Patients with extravesical involvement had worse survival than those with bladder CIS alone [222] (LE: 3).

In the prostate, CIS might be present only in the epithelial lining of the prostatic urethra or in the prostatic ducts [36]. These situations should be distinguished from tumour invasion into the prostatic stroma (stage T4a in bladder tumours), and for which immediate radical cystoprostatectomy is mandatory. Patients with CIS in the epithelial lining of the prostatic urethra can be treated by intravesical instillation of BCG. Transurethral resection of the prostate can improve contact of BCG with the prostatic urethra [95, 223] (LE: 3).


In patients with prostatic duct involvement, there are promising results after BCG instillation, but only from small series, so the data are insufficient to provide clear treatment recommendations and radical surgery should be considered [223, 224] (LE: 3). Treatment of CIS that involves the UUT is discussed in the Guidelines on Urothelial Tumours of the Upper Urinary Tract [1].

7.2.4.5 *Summary of evidence – treatment of CIS*

	LE
CIS cannot be cured by an endoscopic procedure alone.	4
Compared to intravesical chemotherapy, BCG treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression.	1b

BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ.

Flowchart 7.1: Treatment strategy in primary or recurrent tumour(s) without previous BCG*



*For details and explanations see the text of the guidelines

BCG = bacillus Calmette-Guérin; GR = grade of recommendation; MIBC = muscle-invasive bladder cancer; PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

7.3 Treatment of failure of intravesical therapy

7.3.1 Failure of intravesical chemotherapy

Patients with non-muscle-invasive recurrence of BC after a chemotherapy regimen can benefit from BCG instillations. Prior intravesical chemotherapy has no impact on the effect of BCG instillation [176] (LE: 1a).

7.3.2 Recurrence and failure after intravesical BCG immunotherapy

Categories of unsuccessful treatment with intravesical BCG are presented in Table 7.2.

Table 7.2: Categories of unsuccessful treatment with intravesical BCG

BCG failure
Whenever a MIBC is detected during follow-up.
BCG-refractory tumour: 1. If high-grade, non-muscle-invasive papillary tumour is present at 3 months [225]. Further conservative treatment with BCG is associated with increased risk of progression [149, 226] (LE: 3). 2. If CIS (without concomitant papillary tumour) is present at both 3 and 6 months. If patients with CIS present at 3 months, an additional BCG course can achieve a complete response in > 50% of cases [36] (LE: 3). 3. If high-grade tumour appears during BCG therapy*.
High-grade recurrence after BCG. Recurrence of high-grade/grade 3 (WHO 2004/1973) tumour after completion of BCG maintenance, despite an initial response [227] (LE: 3).
BCG intolerance
Severe side effects that prevent further BCG instillation before completing induction [204].

* Patients with low-grade recurrence during or after BCG treatment are not considered to be a BCG failure. BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; WHO = World Health Organization.

7.3.3 Treatment of BCG failure and recurrences after BCG

Treatment recommendations are provided in Section 7.5 and Table 7.7. They reflect the categories mentioned in Table 7.2 and tumour characteristics at the time of recurrence.

Patients with BCG failure are unlikely to respond to further BCG therapy; RC is therefore the preferred option. Various studies suggest that repeat BCG therapy is appropriate for non-high-grade and even for some high-grade recurrent tumours [228, 229] (LE: 3). Additionally, there are now several bladder preservation strategies available that can be categorised as immunotherapy [230] chemotherapy, device-assisted therapy (see 7.2.1.3.2), and combination therapy (see 7.2.3) [231]. Changing from BCG to these options can yield responses in selected cases with BCG treatment failure [228, 232-239] (LE: 3).

Treatments other than RC must be considered oncologically inferior in patients with BCG failure at the present time [149, 225, 226] (LE: 3).

Little is known about the optimal treatment in patients with high-risk tumours who could not complete BCG instillations because of intolerance.


Non-high-grade recurrence after BCG is not considered as BCG failure. Treatment decision should be individualised according to tumour characteristics. It could include chemotherapy or repeat BCG instillations, but the published evidence is very low.

7.3.4 Summary of evidence - treatment failure of intravesical therapy

	LE
Prior intravesical chemotherapy has no impact on the effect of BCG instillation.	1a
Treatments other than radical cystectomy must be considered oncologically inferior in patients with BCG failure.	3

BCG = bacillus Calmette-Guérin.

Flowchart 7.2: Treatment strategy in recurrence during or after intravesical BCG*



*For details and explanations, see the text of the guidelines.

BCG = bacillus Calmette-Guérin; HG = high-grade; IVU = intravenous urography; LG = low-grade;

PDD = photodynamic diagnosis; TURB = transurethral resection of the bladder.

7.4 Radical cystectomy for NMIBC

If RC is indicated before progression to muscle-invasive tumour, it can be performed as an immediate (immediately after NMIBC diagnosis) or early (after BCG failure) procedure.

There are several reasons to consider immediate RC for selected patients with NMIBC:

- The staging accuracy for T1 tumours by TURB is low with 27-51% of patients being upstaged to muscle-invasive tumour at RC [111, 131, 240-245] (LE: 3).
- Some patients with NMIBC experience disease progression to muscle-invasive disease (Table 6.2).

The potential benefit of RC must be weighed against the risk, morbidity, and impact on quality of life. It is reasonable to propose immediate RC in those patients with NMIBC who are at highest risk of progression (see

Section 7.6) [49, 109, 136, 137, 246] (LE: 3).

The benefits and risks of immediate and delayed RC should be discussed with patients. Individual additional prognostic factors in T1 tumours mentioned in Sections 6.1 and 4.6 should be considered.

Early RC is strongly recommended in patients with BCG-refractory tumours, as mentioned above. A delay in RC might lead to decreased disease-specific survival [247] (LE: 3). In patients in whom RC is performed at the time of pathological NMIBC, the 5-year disease-free survival rate exceeds 80% [248-252] (LE: 3).

7.5 Recommendations for adjuvant therapy in Ta, T1 tumours and for therapy of CIS

Recommendation	GR
Smokers with confirmed NMIBC should be counseled to stop smoking.	B
The type of further therapy after TURB should be based on the risk groups shown in Table 6.3 and Section 7.6.	A
In patients with tumours presumed to be at low risk and in those presumed to be at intermediate risk with previous low recurrence rate (less than or equal to one recurrence per year) and expected EORTC recurrence score < 5, one immediate chemotherapy instillation is recommended.	A
In patients with intermediate-risk tumours (with or without immediate instillation), 1-year full-dose BCG treatment (induction plus 3 weekly instillations at 3,6 and 12 months), or instillations of chemotherapy (the optimal schedule is not known) for a maximum of 1 year is recommended. The final choice should reflect the individual patient's risk of recurrence and progression as well as the efficacy and side effects of each treatment modality.	A
In patients with high-risk tumours, full-dose intravesical BCG for 1-3 years (induction plus 3 weekly instillations at 3,6, 12, 18, 24, 30 and 36 months), is indicated. The additional beneficial effect of the second and third years of maintenance should be weighed against its added costs and inconveniences.	A
In patients with CIS in the epithelial lining of the prostatic urethra, TUR of the prostate followed by intravesical instillation of BCG can be offered.	C
In patients at highest risk of tumour progression (Section 7.6), immediate radical cystectomy should be considered.	C
In patients with BCG failure, radical cystectomy is indicated.	B
Intravesical chemotherapy	
One immediate instillation of chemotherapy should be administered within 24 hours after TURB, preferably within 2 hours.	C
One immediate instillation of chemotherapy should be omitted in any case of overt or suspected intra- or extra-peritoneal perforation (after extensive TURB, or bleeding requiring bladder irrigation).	C
Give clear instructions to the nursing staff to control the free flow of the bladder catheter at the end of the immediate instillation.	C
The optimal schedule of further intravesical chemotherapy instillation and its duration is not defined, it should not exceed 1 year.	C
If intravesical chemotherapy is given, it is advised to use the drug at its optimal pH and to maintain the concentration of the drug by reducing fluid intake before and during instillation.	B
The length of individual instillation should be 1-2 hours.	C
BCG intravesical immunotherapy	
Absolute contraindications of BCG intravesical instillation are: <ul style="list-style-type: none"> • during the first 2 weeks after TURB; • in patients with visible haematuria; • after traumatic catheterisation; • in patients with symptomatic urinary tract infection. 	C
The management of side effects after BCG intravesical instillation should reflect their type and grade (Table 7.1).	C

BCG = *bacillus Calmette-Guérin*; CIS = *carcinoma in situ*; TUR = *transurethral resection*; TURB = *transurethral resection of the bladder*.

7.6 Treatment recommendations in Ta, T1 tumours and CIS according to risk stratification

Risk category	Definition	Treatment recommendation
Low-risk tumours	Primary, solitary, Ta, G1/PUNLMP, LG, < 3 cm, no CIS	One immediate instillation of intravesical chemotherapy after TURB.
Intermediate-risk tumours	All cases between categories of low and high risk	In patients with previous low recurrence rate (less than or equal to one recurrence per year) and expected EORTC recurrence score < 5, one immediate instillation of intravesical chemotherapy after TURB. In all patients either 1-year full-dose BCG treatment (induction plus 3-weekly instillations at 3,6 and 12 months), or instillations of chemotherapy (the optimal schedule is not known) for a maximum of 1 year.
High-risk tumours	Any of the following: <ul style="list-style-type: none"> • T1 tumours; • HG/G3 tumours; • CIS; • Multiple and recurrent and large (> 3 cm) Ta G1G2 tumours (all these conditions must be presented). 	Intravesical full-dose BCG instillations for 1-3 years or cystectomy (in highest-risk tumours - see below).
	Subgroup of highest-risk tumours	
	T1G3/HG associated with concurrent bladder CIS, multiple and/or large T1G3/HG and/or recurrent T1G3/HG, T1G3/HG with CIS in the prostatic urethra, unusual histology of urothelial carcinoma, LVI (see Sections 4.6 and 6.2).	Radical cystectomy should be considered, in those who refuse intravesical full-dose BCG instillations for 1-3 years.
	BCG failures.	Radical cystectomy is recommended.

BCG = bacillus Calmette-Guérin; CIS = carcinoma in situ; HG = high-grade; LG = low-grade; LVI = lymphovascular invasion; TURB = transurethral resection of the bladder.

7.7 Treatment recommendations for BCG failure and recurrences after BCG

Category	Treatment recommendation	GR
BCG-refractory tumour	1. Radical cystectomy	B
	2. Bladder-preserving strategies in patients unsuitable for cystectomy	
HG recurrence after BCG	1. Radical cystectomy	C
	2. Repeat BCG course	
	3. Bladder-preserving strategies	
Non-HG recurrence after BCG for primary intermediate-risk tumour	1. Repeat BCG or intravesical chemotherapy	C
	2. Radical cystectomy	

BCG = bacillus Calmette-Guérin; HG = high-grade.

8. FOLLOW-UP OF PATIENTS WITH NMIBC

As a result of the risk of recurrence and progression, patients with NMIBC need to be followed up. However, the frequency and duration of cystoscopy and imaging should reflect the individual patient's degree of risk. Using risk tables (see Tables 6.1 and 6.2), the short- and long-term risks of recurrence and progression in individual patients may be predicted and the follow-up schedule adapted accordingly [136, 137].

When planning the follow-up schedule and methods, the following aspects should be considered:

- The prompt detection of muscle-invasive and HG/G3 non-muscle-invasive recurrence is crucial because a delay in diagnosis and therapy can be life-threatening.
- Tumour recurrence in the low-risk group is nearly always low stage and LG/G1. Small, Ta LG/G1 papillary recurrence does not present an immediate danger to the patient and early detection is not essential for successful therapy [253-257] (LE: 2b). Fulguration of small papillary recurrences on an outpatient basis could be a safe option that reduces the therapeutic burden [101] (LE: 3). Some authors have even defended temporary surveillance in selected cases [256-258] (LE: 3).
- The first cystoscopy after TURB at 3 months is an important prognostic indicator for recurrence and progression [143, 149, 259-261] (LE: 1a). Therefore, the first cystoscopy should always be performed 3 months after TURB in all patients with Ta, T1 tumours and CIS.
- In tumours at low-risk, the risk of recurrence after 5 recurrence-free years is low [260] (LE: 3). Discontinuation of cystoscopy or its replacement with less-invasive methods can be considered [261].
- In tumours originally intermediate- or high-risk, recurrences after 10 years tumour-free are not unusual [262] (LE: 3). Therefore, life-long follow-up is recommended [261].
- The follow-up strategy must reflect the risk of extravesical recurrence (prostatic urethra in men and UUT)
- The risk of UUT recurrence increases in patients with multiple- and high-risk tumours [65] (LE: 3).
- Positive urine test results have a positive impact on the quality of performed follow-up cystoscopy [93] (LE: 1b). It supports the adjunctive role of urine tests during follow-up.

No non-invasive method can replace endoscopy. Follow-up is therefore based on regular cystoscopy (see Section 5.7). There is a lack of randomised studies that have investigated the possibility of safely reducing the frequency of follow-up cystoscopy.

As CIS is often not visible, multiple biopsies may be necessary in selected cases to confirm the efficacy of intravesical treatment in patients treated for CIS [94]. The following recommendations are based mostly on retrospective data.

8.1 Summary of evidence - follow-up of patients with NMIBC

	LE
The first cystoscopy after TURB at 3 months is an important prognostic indicator for recurrence and progression.	1a
The risk of UUT recurrence increases in patients with multiple- and high-risk tumours.	3

TURB = transurethral resection of the bladder; UUT = upper urinary tract.

8.2 Recommendations for follow-up in patients after TURB of NMIBC

Recommendations	GR
The follow-up of Ta, T1 tumours and CIS is based on regular cystoscopy.	A
Patients with low-risk Ta tumours should undergo cystoscopy at 3 months. If negative, subsequent cystoscopy is advised 9 months later, and then yearly for 5 years.	C
Patients with high-risk tumours should undergo cystoscopy and urinary cytology at 3 months. If negative, subsequent cystoscopy and cytology should be repeated every 3 months for a period of 2 years, and every 6 months thereafter until 5 years, and then yearly.	C
Patients with intermediate-risk Ta tumours should have an in-between follow-up scheme using cystoscopy and cytology, which is adapted according to personal and subjective factors.	C
Regular (yearly) upper tract imaging (CT-IVU or IVU) is recommended for high-risk tumours.	C
Endoscopy under anaesthesia and bladder biopsies should be performed when office cystoscopy shows suspicious findings or if urinary cytology is positive.	B
Consider R-biopsies or biopsies with PDD after intravesical treatment (at 3 or 6 months) in patients with CIS.	C
During follow-up in patients with positive cytology and no visible tumour in the bladder, R-biopsies or PDD-guided biopsies (if equipment is available) and investigation of extravesical locations (CT urography, prostatic urethra biopsy) are recommended.	B

CIS = carcinoma in situ; CT-IVU = computed tomography intravenous urography; IVU = intravenous urography; PDD = photodynamic diagnosis; R-biopsies = random biopsies.

9. REFERENCES

- Rouprêt M., *et al.* EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract. In: EAU Guidelines. Edn. presented at the EAU Annual Congress Munich 2016, European Association of Urology, Guidelines Office, Arnhem, The Netherlands.
<http://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/>
- Witjes JA., *et al.* EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. In: EAU Guidelines. Edition presented at the EAU Annual Congress Munich 2016. European Association of Urology, Arnhem, The Netherlands.
<http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/>
- Gakis G., *et al.* Guidelines on Primary Urethral Carcinoma. Edition presented at the EAU Annual Congress Munich 2016. European Association of Urology, Arnhem, The Netherlands.
<http://uroweb.org/guideline/primary-urethral-carcinoma/>
- Sylvester, R.J. *et al.* Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? *Eur Urol*, 2015.
<http://www.ncbi.nlm.nih.gov/pubmed/26091833>
- Phillips B., *et al.* Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.
<http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
- Hernandez V., *et al.* Is there a difference between the 2004 WHO grading system and the 1973 WHO grading system for NMIBC in terms of prognostic performance? in PROSPERO International prospective register of systematic reviews. 2015, University of York.
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015025045
- Ferlay J., *et al.* GLOBOCAN 2012 v1.0: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2015.
<http://www.iarc.fr/en/publications/eresources/cancerbases/index.php>
- Burger, M., *et al.* Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*, 2013. 63: 234.
<http://www.ncbi.nlm.nih.gov/pubmed/22877502>
- Bosetti, C., *et al.* Trends in mortality from urologic cancers in Europe, 1970-2008. *Eur Urol*, 2011. 60: 1.
<http://www.ncbi.nlm.nih.gov/pubmed/21497988>

10. Chavan, S., *et al.* International variations in bladder cancer incidence and mortality. *Eur Urol*, 2014. 66: 59.
<http://www.ncbi.nlm.nih.gov/pubmed/24451595>
11. Steinmaus, C., *et al.* Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. *Cancer Epidemiol Biomarkers Prev*, 2014. 23: 1529.
<http://www.ncbi.nlm.nih.gov/pubmed/24859871>
12. Freedman, N.D., *et al.* Association between smoking and risk of bladder cancer among men and women. *JAMA*, 2011. 306: 737.
<http://www.ncbi.nlm.nih.gov/pubmed/21846855>
13. Martini, T., *et al.* Validation of RiskCheck Bladder Cancer (c), version 5.0 for risk-adapted screening of bladder cancer. *Urol Int*, 2013. 91: 175.
<http://www.ncbi.nlm.nih.gov/pubmed/23860006>
14. Mir, M.C., *et al.* Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. *Cancer Epidemiol Biomarkers Prev*, 2013. 22: 2241.
<http://www.ncbi.nlm.nih.gov/pubmed/24089460>
15. Rushton, L., *et al.* Occupational cancer burden in Great Britain. *Br J Cancer*, 2012. 107 Suppl 1: S3.
<http://www.ncbi.nlm.nih.gov/pubmed/22710676>
16. Samanic, C.M., *et al.* Occupation and bladder cancer in a hospital-based case-control study in Spain. *Occup Environ Med*, 2008. 65: 347.
<http://www.ncbi.nlm.nih.gov/pubmed/17951336>
17. Colt, J.S., *et al.* A case-control study of occupational exposure to metalworking fluids and bladder cancer risk among men. *Occup Environ Med*, 2014. 71: 667.
<http://www.ncbi.nlm.nih.gov/pubmed/25018457>
18. Pesch, B., *et al.* Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. *Int Arch Occup Environ Health*, 2013.
<http://www.ncbi.nlm.nih.gov/pubmed/24129706>
19. Egbers, L., *et al.* The prognostic value of family history among patients with urinary bladder cancer. *Int J Cancer*, 2015. 136: 1117.
<http://www.ncbi.nlm.nih.gov/pubmed/24978702>
20. Corral, R., *et al.* Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. *Int J Cancer*, 2014. 135: 335.
<http://www.ncbi.nlm.nih.gov/pubmed/24382701>
21. Rafnar, T., *et al.* European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. *Hum Mol Genet*, 2011. 20: 4268.
<http://www.ncbi.nlm.nih.gov/pubmed/21750109>
22. Ros, M.M., *et al.* Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer*, 2011. 128: 2695.
<http://www.ncbi.nlm.nih.gov/pubmed/20715171>
23. Koutros, S., *et al.* Hair dye use and risk of bladder cancer in the New England bladder cancer study. *Int J Cancer*, 2011. 129: 2894.
<http://www.ncbi.nlm.nih.gov/pubmed/21678399>
24. Ros, M.M., *et al.* Personal hair dye use and the risk of bladder cancer: a case-control study from The Netherlands. *Cancer Causes Control*, 2012. 23: 1139.
<http://www.ncbi.nlm.nih.gov/pubmed/22581032>
25. Buckland, G., *et al.* Adherence to the Mediterranean diet and risk of bladder cancer in the EPIC cohort study. *Int J Cancer*, 2014. 134: 2504.
<http://www.ncbi.nlm.nih.gov/pubmed/24226765>
26. Sobin LH., *et al.* TNM classification of malignant tumors. UICC International Union Against Cancer. 7th Edn. Wiley-Blackwell. 2009. 262.
<http://www.uicc.org/tnm/>
27. Epstein, J.I., *et al.* The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. *Am J Surg Pathol*, 1998. 22: 1435.
<http://www.ncbi.nlm.nih.gov/pubmed/9850170>
28. Sauter G., *et al.* Tumours of the urinary system: non-invasive urothelial neoplasias. In: WHO classification of classification of tumours of the urinary system and male genital organs. IARCC Press: Lyon. 2004. 29
<http://www.iarc.fr/en/publications/pdfs-online/pat-gen/index.php>

29. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th edn. 2016, Lyon, France.
30. MacLennan, G.T., *et al.* Histologic grading of noninvasive papillary urothelial neoplasms. *Eur Urol*, 2007. 51: 889.
<http://www.ncbi.nlm.nih.gov/pubmed/17095142>
31. van Rhijn, B.W., *et al.* The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. *Eur Urol*, 2010. 57: 1052.
<http://www.ncbi.nlm.nih.gov/pubmed/19765886>
32. Pan, C.C., *et al.* *Am J Clin Pathol*, 2010. 133: 788.
<http://www.ncbi.nlm.nih.gov/pubmed/20395527>
33. Burger, M., *et al.* Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. *Eur Urol*, 2008. 54: 835.
<http://www.ncbi.nlm.nih.gov/pubmed/18166262>
34. May, M., *et al.* Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. *Eur Urol*, 2010. 57: 850.
<http://www.ncbi.nlm.nih.gov/pubmed/19346063>
35. Otto, W., *et al.* The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. *BJU Int*, 2011. 107: 404.
<http://www.ncbi.nlm.nih.gov/pubmed/20707791>
36. Sylvester, R.J., *et al.* High-grade Ta urothelial carcinoma and carcinoma *in situ* of the bladder. *Urology*, 2005. 66: 90.
<http://www.ncbi.nlm.nih.gov/pubmed/16399418>
37. Lamm, D., *et al.* Updated concepts and treatment of carcinoma *in situ*. *Urol Oncol*, 1998. 4: 130.
<http://www.ncbi.nlm.nih.gov/pubmed/21227218>
38. Murphy, W.M., *et al.* Interobserver discrepancy using the 1998 World Health Organization/ International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. *J Urol*, 2002. 168: 968.
<http://www.ncbi.nlm.nih.gov/pubmed/12187201>
39. Witjes, J.A., *et al.* Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. *Urology*, 2006. 67: 751.
<http://www.ncbi.nlm.nih.gov/pubmed/16566990>
40. Bol, M.G., *et al.* Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. *J Urol*, 2003. 169: 1291.
<http://www.ncbi.nlm.nih.gov/pubmed/12629345>
41. Van Der Meijden, A., *et al.* The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. *J Urol*, 2000. 164: 1533.
<http://www.ncbi.nlm.nih.gov/pubmed/11025698>
42. van Rhijn, B.W., *et al.* Pathological stage review is indicated in primary pT1 bladder cancer. *BJU Int*, 2010. 106: 206.
<http://www.ncbi.nlm.nih.gov/pubmed/20002439>
43. Comp erat, E., *et al.* An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. *Histopathology*, 2013. 63: 756.
<http://www.ncbi.nlm.nih.gov/pubmed/24102813>
44. Mangrud, O.M., *et al.* Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder. *PLoS One*, 2014. 9: e83192.
<http://www.ncbi.nlm.nih.gov/pubmed/24409280>
45. Orsola, A., *et al.* Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. *Eur Urol*, 2005. 48: 231.
<http://www.ncbi.nlm.nih.gov/pubmed/15963635>
46. Andius, P., *et al.* Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. *Urology*, 2007. 70: 758.
<http://www.ncbi.nlm.nih.gov/pubmed/17991551>
47. van Rhijn, B.W., *et al.* A new and highly prognostic system to discern T1 bladder cancer substage. *Eur Urol*, 2012. 61: 378.
<http://www.ncbi.nlm.nih.gov/pubmed/22036775>

48. van Rhijn, B.W., *et al.* Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. *BJU Int*, 2012. 110: 1169.
<http://www.ncbi.nlm.nih.gov/pubmed/22448597>
49. Kamat, A.M., *et al.* The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. *J Urol*, 2006. 175: 881.
<http://www.ncbi.nlm.nih.gov/pubmed/16469571>
50. Cho, K.S., *et al.* Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. *J Urol*, 2009. 182: 2625.
<http://www.ncbi.nlm.nih.gov/pubmed/19836779>
51. Compérat, E., *et al.* Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. *Pathology*, 2010. 42: 650.
<http://www.ncbi.nlm.nih.gov/pubmed/21080874>
52. Amin, A., *et al.* Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases. *Hum Pathol*, 2012. 43: 2124.
<http://www.ncbi.nlm.nih.gov/pubmed/22939957>
53. Blochin, E.B., *et al.* Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. *Mod Pathol*, 2012. 25: 1534.
<http://www.ncbi.nlm.nih.gov/pubmed/22766788>
54. Wasco, M.J., *et al.* Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. *Urology*, 2007. 70: 69.
<http://www.ncbi.nlm.nih.gov/pubmed/17656211>
55. Kaimakliotis, H.Z., *et al.* Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? *Urol Oncol*, 2014. 32: 833.
<http://www.ncbi.nlm.nih.gov/pubmed/24954925>
56. Willis, D.L., *et al.* Micropapillary bladder cancer: current treatment patterns and review of the literature. *Urol Oncol*, 2014. 32: 826.
<http://www.ncbi.nlm.nih.gov/pubmed/24931270>
57. Beltran, A.L., *et al.* Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. *Virchows Arch*, 2014. 465: 199.
<http://www.ncbi.nlm.nih.gov/pubmed/24878757>
58. Frstrup, N., *et al.* Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. *Am J Pathol*, 2012. 180: 1824.
<http://www.ncbi.nlm.nih.gov/pubmed/22449953>
59. Palou, J., *et al.* Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin. *Eur Urol*, 2009. 56: 829.
<http://www.ncbi.nlm.nih.gov/pubmed/18926620>
60. van Rhijn, B.W., *et al.* The FGFR3 mutation is related to favorable pT1 bladder cancer. *J Urol*, 2012. 187: 310.
<http://www.ncbi.nlm.nih.gov/pubmed/22099989>
61. Nolte-Ernsting, C., *et al.* Understanding multislice CT urography techniques: Many roads lead to Rome. *Eur Radiol*, 2006. 16: 2670.
<http://www.ncbi.nlm.nih.gov/pubmed/16953373>
62. Goessl, C., *et al.* Is routine excretory urography necessary at first diagnosis of bladder cancer? *J Urol*, 1997. 157: 480.
<http://www.ncbi.nlm.nih.gov/pubmed/8996338>
63. Palou, J., *et al.* Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. *J Urol*, 2005. 174: 859.
<http://www.ncbi.nlm.nih.gov/pubmed/16093970>
64. Holmäng, S., *et al.* Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. *J Urol*, 1998. 160: 45.
<http://www.ncbi.nlm.nih.gov/pubmed/9628602>
65. Millan-Rodriguez, F., *et al.* Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. *J Urol*, 2000. 164: 1183.
<http://www.ncbi.nlm.nih.gov/pubmed/10992362>
66. Yafi, F.A., *et al.* Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. *Urol Oncol*, 2015. 33: 66 e25.
<http://www.ncbi.nlm.nih.gov/pubmed/25037483>

67. Têtu, B. Diagnosis of urothelial carcinoma from urine. *Mod Pathol*, 2009. 22 Suppl 2: S53.
<http://www.ncbi.nlm.nih.gov/pubmed/19494853>
68. Raitanen, M.P., *et al.* Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. *Eur Urol*, 2002. 41: 284.
<http://www.ncbi.nlm.nih.gov/pubmed/12180229>
69. Lokeshwar, V.B., *et al.* Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. *Urology*, 2005. 66: 35.
<http://www.ncbi.nlm.nih.gov/pubmed/16399415>
70. Burton, J.L., *et al.* Demand management in urine cytology: a single cytospin slide is sufficient. *J Clin Pathol*, 2000. 53: 718.
<http://www.ncbi.nlm.nih.gov/pubmed/11041065>
71. Nabi, G., *et al.* Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? *J Clin Pathol*, 2004. 57: 365.
<http://www.ncbi.nlm.nih.gov/pubmed/15047737>
72. Glas, A.S., *et al.* Tumor markers in the diagnosis of primary bladder cancer. A systematic review. *J Urol*, 2003. 169: 1975.
<http://www.ncbi.nlm.nih.gov/pubmed/12771702>
73. van Rhijn, B.W., *et al.* Urine markers for bladder cancer surveillance: a systematic review. *Eur Urol*, 2005. 47: 736.
<http://www.ncbi.nlm.nih.gov/pubmed/15925067>
74. Vrooman, O.P., *et al.* Urinary markers in bladder cancer. *Eur Urol*, 2008. 53: 909.
<http://www.ncbi.nlm.nih.gov/pubmed/18162285>
75. Lotan, Y., *et al.* Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol*, 2010. 28: 441.
<http://www.ncbi.nlm.nih.gov/pubmed/20610281>
76. Van Rhijn BWG, *et al.* Cytology and urinary markers for the diagnosis of bladder cancer. *Eur Urol Suppl*, 2009: 536.
https://www.researchgate.net/profile/Theodorus_Van_der_Kwast/publication/228373501_Cytology_and_Urinary_Markers_for_the_Diagnosis_of_Bladder_Cancer/links/02e7e51dae7ec70942000000.pdf
77. Catto, JWF. Old and new urinary markers: Which one is the PSA for bladder cancer?. *Eur Urol Suppl*, 2008: 422.
[http://www.europeanurology.com/article/S1569-9056\(07\)00237-0/fulltext/old-and-new-urinary-markers-which-one-is-the-psa-for-bladder-cancer-img-src-manager-uploads-europeanurology-com-eur-articles-s1569-9056-07-00237-0-assets-eulogo1-jpg-alt-eulogo1](http://www.europeanurology.com/article/S1569-9056(07)00237-0/fulltext/old-and-new-urinary-markers-which-one-is-the-psa-for-bladder-cancer-img-src-manager-uploads-europeanurology-com-eur-articles-s1569-9056-07-00237-0-assets-eulogo1-jpg-alt-eulogo1)
78. Yutkin, V., *et al.* Can urinary biomarkers replace cystoscopic examination in bladder cancer surveillance? *Expert Rev Anticancer Ther*, 2010. 10: 787.
<http://www.ncbi.nlm.nih.gov/pubmed/20553203>
79. Agarwal, P.K., *et al.* Considerations on the use of diagnostic markers in management of patients with bladder cancer. *World J Urol*, 2008. 26: 39.
<http://www.ncbi.nlm.nih.gov/pubmed/18092171>
80. Hajdinjak, T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. *Urol Oncol*, 2008. 26: 646.
<http://www.ncbi.nlm.nih.gov/pubmed/18367109>
81. Schlomer, B.J., *et al.* Prospective validation of the clinical usefulness of reflex fluorescence *in situ* hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *J Urol*, 2010. 183: 62.
<http://www.ncbi.nlm.nih.gov/pubmed/19913822>
82. Kamat, A.M., *et al.* Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. *BJU Int*, 2011. 108: 1119.
<http://www.ncbi.nlm.nih.gov/pubmed/21426474>
83. Bergman, J., *et al.* Surveillance of patients with bladder carcinoma using fluorescent *in-situ* hybridization on bladder washings. *BJU Int*, 2008. 101: 26.
<http://www.ncbi.nlm.nih.gov/pubmed/17850364>
84. van der Aa, M.N., *et al.* Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). *Eur Urol*, 2009. 55: 659.
<http://www.ncbi.nlm.nih.gov/pubmed/18501499>

85. de Bekker-Grob, E.W., *et al.* Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? *BJU Int*, 2009. 104: 41.
<http://www.ncbi.nlm.nih.gov/pubmed/19500328>
86. Rouprêt, M., *et al.* A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. *BJU Int*, 2008. 101: 1448.
<http://www.ncbi.nlm.nih.gov/pubmed/18325051>
87. Grossman, H.B., *et al.* Detection of bladder cancer using a point-of-care proteomic assay. *JAMA*, 2005. 293: 810.
<http://www.ncbi.nlm.nih.gov/pubmed/15713770>
88. Kim, H.S., *et al.* Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: A systematic review and meta-analysis. *Urol Oncol*, 2014. 32: 1191.
<http://www.ncbi.nlm.nih.gov/pubmed/24954108>
89. Lotan, Y., *et al.* Screening for bladder cancer: a perspective. *World J Urol*, 2008. 26: 13.
<http://www.ncbi.nlm.nih.gov/pubmed/18030473>
90. Roobol, M.J., *et al.* Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). *Urol Oncol*, 2010. 28: 686.
<http://www.ncbi.nlm.nih.gov/pubmed/21062653>
91. Grossman, H.B., *et al.* Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. *JAMA*, 2006. 295: 299.
<http://www.ncbi.nlm.nih.gov/pubmed/16418465>
92. Babjuk, M., *et al.* Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pT_apT₁ bladder urothelial carcinoma. *Urology*, 2008. 71: 718.
<http://www.ncbi.nlm.nih.gov/pubmed/18387400>
93. van der Aa, M.N., *et al.* Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. *J Urol*, 2010. 183: 76.
<http://www.ncbi.nlm.nih.gov/pubmed/19913254>
94. Kurth, K.H., *et al.* Current methods of assessing and treating carcinoma *in situ* of the bladder with or without involvement of the prostatic urethra. *Int J Urol*, 1995. 2 Suppl 2: 8.
<http://www.ncbi.nlm.nih.gov/pubmed/7553309>
95. Aaronson, D.S., *et al.* Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? *BJU Int*, 2009. 104: 506.
<http://www.ncbi.nlm.nih.gov/pubmed/19239453>
96. Richterstetter, M., *et al.* The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. *BJU Int*, 2012. 110: E76.
<http://www.ncbi.nlm.nih.gov/pubmed/22313727>
97. Herr, H.W., *et al.* Quality control in transurethral resection of bladder tumours. *BJU Int*, 2008. 102: 1242.
<http://www.ncbi.nlm.nih.gov/pubmed/19035888>
98. Brausi, M., *et al.* Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage T_a T₁ transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. *Eur Urol*, 2002. 41: 523.
<http://www.ncbi.nlm.nih.gov/pubmed/12074794>
99. Mariappan, P., *et al.* Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. *Eur Urol*, 2010. 57: 843.
<http://www.ncbi.nlm.nih.gov/pubmed/19524354>
100. Mariappan, P., *et al.* Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. *BJU Int*, 2012. 109: 1666.
<http://www.ncbi.nlm.nih.gov/pubmed/22044434>
101. Herr, H.W., *et al.* Management of low grade papillary bladder tumors. *J Urol*, 2007. 178: 1201.
<http://www.ncbi.nlm.nih.gov/pubmed/17698090>
102. Sabir, E.F., *et al.* TaG1 Bladder Cancer: A Third of All Primary Tumors and 80% of All Recurrences Can Be Treated in the Office Using Local Anesthesia. *Urology Practice*. 1: 184.
<http://www.sciencedirect.com/science/article/pii/S2352077914001083>

103. Gupta, N.P., *et al.* Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience. *BJU Int*, 2011. 108: 553.
<http://www.ncbi.nlm.nih.gov/pubmed/21176081>
104. Venkatramani, V., *et al.* Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. *J Urol*, 2014. 191: 1703.
<http://www.ncbi.nlm.nih.gov/pubmed/24333244>
105. Sugihara, T., *et al.* Comparison of Perioperative Outcomes including Severe Bladder Injury between Monopolar and Bipolar Transurethral Resection of Bladder Tumors: A Population Based Comparison. *J Urol*, 2014. 192: 1355.
<http://www.ncbi.nlm.nih.gov/pubmed/24893311>
106. Mashni, J., *et al.* Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. *Int Urol Nephrol*, 2014. 46: 1699.
<http://www.ncbi.nlm.nih.gov/pubmed/24792236>
107. van der Meijden, A., *et al.* Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. *Eur Urol*, 1999. 35: 267.
<http://www.ncbi.nlm.nih.gov/pubmed/10419345>
108. Hara, T., *et al.* Risk of concomitant carcinoma *in situ* determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. *Int J Urol*, 2009. 16: 293.
<http://www.ncbi.nlm.nih.gov/pubmed/19207607>
109. Palou, J., *et al.* Female gender and carcinoma *in situ* in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. *Eur Urol*, 2012. 62: 118.
<http://www.ncbi.nlm.nih.gov/pubmed/22101115>
110. Mungan, M.U., *et al.* Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. *Eur Urol*, 2005. 48: 760.
<http://www.ncbi.nlm.nih.gov/pubmed/16005563>
111. Huguet, J., *et al.* Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. *Eur Urol*, 2005. 48: 53.
<http://www.ncbi.nlm.nih.gov/pubmed/15967252>
112. Kausch, I., *et al.* Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. *Eur Urol*, 2010. 57: 595.
<http://www.ncbi.nlm.nih.gov/pubmed/20004052>
113. Mowatt, G., *et al.* Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. *Int J Technol Assess Health Care*, 2011. 27: 3.
<http://www.ncbi.nlm.nih.gov/pubmed/21262078>
114. Neuzillet, Y., *et al.* Assessment of diagnostic gain with hexaminolevulinic acid (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. *Urol Oncol*, 2014. 32: 1135.
<http://www.ncbi.nlm.nih.gov/pubmed/25023786>
115. Draga, R.O., *et al.* Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. *Eur Urol*, 2010. 57: 655.
<http://www.ncbi.nlm.nih.gov/pubmed/19819064>
116. Ray, E.R., *et al.* Hexylaminolaevulinic acid fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. *BJU Int*, 2010. 105: 789.
<http://www.ncbi.nlm.nih.gov/pubmed/19832725>
117. Schumacher, M.C., *et al.* Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. *Eur Urol*, 2010. 57: 293.
<http://www.ncbi.nlm.nih.gov/pubmed/19913351>
118. Stenzl, A., *et al.* Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial. *Cancer*, 2011. 117: 938.
<http://www.ncbi.nlm.nih.gov/pubmed/21351082>

119. Burger, M., *et al.* Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. *Eur Urol*, 2013. 64: 846.
<http://www.ncbi.nlm.nih.gov/pubmed/23602406>
120. O'Brien, T., *et al.* Prospective randomized trial of hexaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. *BJU Int*, 2013. 112: 1096.
<http://www.ncbi.nlm.nih.gov/pubmed/24053153>
121. Gkritisios, P., *et al.* Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial. *Int Urol Nephrol*, 2014. 46: 927.
<http://www.ncbi.nlm.nih.gov/pubmed/24249423>
122. Cauberg, E.C., *et al.* Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. *Urology*, 2010. 76: 658.
<http://www.ncbi.nlm.nih.gov/pubmed/20223505>
123. Zheng, C., *et al.* Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. *BJU Int*, 2012. 110: E680.
<http://www.ncbi.nlm.nih.gov/pubmed/22985502>
124. Herr, H.W. Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors. *Eur Urol*, 2015. 67: 605.
<http://www.ncbi.nlm.nih.gov/pubmed/25041849>
125. Grimm, M.O., *et al.* Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. *J Urol*, 2003. 170: 433.
<http://www.ncbi.nlm.nih.gov/pubmed/12853793>
126. Divrik, R.T., *et al.* The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. *J Urol*, 2006. 175: 1641.
<http://www.ncbi.nlm.nih.gov/pubmed/16600720>
127. Jahanson, S., *et al.* Results of second-look resection after primary resection of T1 tumour of the urinary bladder. *Scand J Urol Nephrol*, 2005. 39: 206.
<http://www.ncbi.nlm.nih.gov/pubmed/16127800>
128. Lazica, D.A., *et al.* Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. *Urol Int*, 2014. 92: 131.
<http://www.ncbi.nlm.nih.gov/pubmed/23988813>
129. Vasdev, N., *et al.* The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. *Ecancermedicallscience*, 2012. 6: 269.
<http://www.ncbi.nlm.nih.gov/pubmed/22988482>
130. Dalbagni, G., *et al.* Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. *Eur Urol*, 2009. 56: 903.
<http://www.ncbi.nlm.nih.gov/pubmed/19632765>
131. Fritsche, H.M., *et al.* Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol*, 2010. 57: 300.
<http://www.ncbi.nlm.nih.gov/pubmed/19766384>
132. Kulkarni, G.S., *et al.* An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. *Eur Urol*, 2010. 57: 60.
<http://www.ncbi.nlm.nih.gov/pubmed/19740595>
133. Sfakianos, J.P., *et al.* The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. *J Urol*, 2014. 191: 341.
<http://www.ncbi.nlm.nih.gov/pubmed/23973518>
134. Bishr, M., *et al.* Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. *Can Urol Assoc J*, 2014. 8: E306.
<http://www.ncbi.nlm.nih.gov/pubmed/24940455>
135. Lopez-Beltran, A., *et al.* Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. *Eur Urol*, 2004. 45: 257.
<http://www.ncbi.nlm.nih.gov/pubmed/15036668>

136. Sylvester, R.J., *et al.* Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol*, 2006. 49: 466.
<http://www.ncbi.nlm.nih.gov/pubmed/16442208>
137. Fernandez-Gomez, J., *et al.* Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. *J Urol*, 2009. 182: 2195.
<http://www.ncbi.nlm.nih.gov/pubmed/19758621>
138. van Rhijn, B.W., *et al.* Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. *Eur Urol*, 2010. 58: 433.
<http://www.ncbi.nlm.nih.gov/pubmed/20646825>
139. Fernandez-Gomez, J., *et al.* The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. *Eur Urol*, 2011. 60: 423.
<http://www.ncbi.nlm.nih.gov/pubmed/21621906>
140. Cambier, S., *et al.* EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. *Eur Urol*, 2015.
<http://www.ncbi.nlm.nih.gov/pubmed/26210894>
141. Gontero, P., *et al.* Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. *Eur Urol*, 2015. 67: 74.
<http://www.ncbi.nlm.nih.gov/pubmed/25043942>
142. Golijanin, D., *et al.* Carcinoma in a bladder diverticulum: presentation and treatment outcome. *J Urol*, 2003. 170: 1761.
<http://www.ncbi.nlm.nih.gov/pubmed/14532771>
143. Palou, J., *et al.* Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. *Urology*, 2009. 73: 1313.
<http://www.ncbi.nlm.nih.gov/pubmed/19362341>
144. Alkhateeb, S.S., *et al.* Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin. *Urol Ann*, 2011. 3: 119.
<http://www.ncbi.nlm.nih.gov/pubmed/21976923>
145. Lamm, D.L. Carcinoma *in situ*. *Urol Clin North Am*, 1992. 19: 499.
<http://www.ncbi.nlm.nih.gov/pubmed/1636234>
146. Losa, A., *et al.* Low dose bacillus Calmette-Guerin for carcinoma *in situ* of the bladder: long-term results. *J Urol*, 2000. 163: 68.
<http://www.ncbi.nlm.nih.gov/pubmed/10604316>
147. Griffiths, T.R., *et al.* Treatment of carcinoma *in situ* with intravesical bacillus Calmette-Guerin without maintenance. *J Urol*, 2002. 167: 2408.
<http://www.ncbi.nlm.nih.gov/pubmed/11992047>
148. Takenaka, A., *et al.* Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma *in situ* of urinary bladder. *Int J Urol*, 2008. 15: 309.
<http://www.ncbi.nlm.nih.gov/pubmed/18380817>
149. Solsona, E., *et al.* The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. *J Urol*, 2000. 164: 685.
<http://www.ncbi.nlm.nih.gov/pubmed/10953125>
150. van Gils-Gielen, R.J., *et al.* Risk factors in carcinoma *in situ* of the urinary bladder. Dutch South East Cooperative Urological Group. *Urology*, 1995. 45: 581.
<http://www.ncbi.nlm.nih.gov/pubmed/7716838>
151. Lammers, R.J., *et al.* Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. *Eur Urol*, 2011. 60: 713.
<http://www.ncbi.nlm.nih.gov/pubmed/21794974>
152. Rink, M., *et al.* Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. *Eur Urol*, 2012. 62: 1204.
<http://www.ncbi.nlm.nih.gov/pubmed/22980442>
153. Rink, M., *et al.* Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. *J Urol*, 2012. 188: 2120.
<http://www.ncbi.nlm.nih.gov/pubmed/23083868>

154. Crivelli, J.J., *et al.* Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. *Eur Urol*, 2014. 65: 742.
<http://www.ncbi.nlm.nih.gov/pubmed/23810104>
155. Grotenhuis, A.J., *et al.* The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. *Urol Oncol*, 2015. 33: 65 e9.
<http://www.ncbi.nlm.nih.gov/pubmed/25023787>
156. Serretta, V., *et al.* Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. *Urology*, 2013. 81: 277.
<http://www.ncbi.nlm.nih.gov/pubmed/23374781>
157. Soloway, M.S., *et al.* Urothelial susceptibility to tumor cell implantation: influence of cauterization. *Cancer*, 1980. 46: 1158.
<http://www.ncbi.nlm.nih.gov/pubmed/7214299>
158. Pan, J.S., *et al.* Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. *J Urol*, 1989. 142: 1589.
<http://www.ncbi.nlm.nih.gov/pubmed/2511340>
159. Brocks, C.P., *et al.* Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. *J Urol*, 2005. 174: 1115.
<http://www.ncbi.nlm.nih.gov/pubmed/16094076>
160. Oosterlinck, W., *et al.* A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. *J Urol*, 1993. 149: 749.
<http://www.ncbi.nlm.nih.gov/pubmed/8455236>
161. Sylvester, R.J., *et al.* A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. *J Urol*, 2004. 171: 2186.
<http://www.ncbi.nlm.nih.gov/pubmed/15126782>
162. Abern, M.R., *et al.* Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *J Natl Compr Canc Netw*, 2013. 11: 477.
<http://www.ncbi.nlm.nih.gov/pubmed/23584348>
163. Perlis, N., *et al.* Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. *Eur Urol*, 2013. 64: 421.
<http://www.ncbi.nlm.nih.gov/pubmed/23830475>
164. Pode, D., *et al.* The mechanism of human bladder tumor implantation in an in vitro model. *J Urol*, 1986. 136: 482.
<http://www.ncbi.nlm.nih.gov/pubmed/3525861>
165. Günther, J.H., *et al.* Optimizing syngeneic orthotopic murine bladder cancer (MB49). *Cancer Res*, 1999. 59: 2834.
<http://www.ncbi.nlm.nih.gov/pubmed/10383142>
166. Böhle, A., *et al.* Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. *J Urol*, 2002. 167: 357.
<http://www.ncbi.nlm.nih.gov/pubmed/11743356>
167. Oddens, J.R., *et al.* One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? *Eur Urol*, 2004. 46: 336.
<http://www.ncbi.nlm.nih.gov/pubmed/15306104>
168. Elmamoun, M.H., *et al.* Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent. *BJU Int*, 2014. 113: E34.
<http://www.ncbi.nlm.nih.gov/pubmed/24053461>
169. Bouffieux, C., *et al.* Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. *European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol*, 1995. 153: 934.
<http://www.ncbi.nlm.nih.gov/pubmed/7853578>
170. Kaasinen, E., *et al.* Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. *Eur Urol*, 2002. 42: 167.
<http://www.ncbi.nlm.nih.gov/pubmed/12160589>

171. Sylvester, R.J., *et al.* The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. *Eur Urol*, 2008. 53: 709.
<http://www.ncbi.nlm.nih.gov/pubmed/18207317>
172. Tolley, D.A., *et al.* The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. *J Urol*, 1996. 155: 1233.
<http://www.ncbi.nlm.nih.gov/pubmed/8632538>
173. Huncharek, M., *et al.* Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. *Anticancer Res*, 2001. 21: 765.
<http://www.ncbi.nlm.nih.gov/pubmed/11299841>
174. Böhle, A., *et al.* Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. *Urology*, 2004. 63: 682.
<http://www.ncbi.nlm.nih.gov/pubmed/15072879>
175. Sylvester, R.J., *et al.* Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol*, 2002. 168: 1964.
<http://www.ncbi.nlm.nih.gov/pubmed/12394686>
176. Malmström, P.U., *et al.* An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. *Eur Urol*, 2009. 56: 247.
<http://www.ncbi.nlm.nih.gov/pubmed/19409692>
177. Sylvester, R.J., *et al.* Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. *Eur Urol*, 2010. 57: 766.
<http://www.ncbi.nlm.nih.gov/pubmed/20034729>
178. Shang, P.F., *et al.* Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. *Cochrane Database Syst Rev*, 2011: CD006885.
<http://www.ncbi.nlm.nih.gov/pubmed/21563157>
179. Au, J.L., *et al.* Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. *J Natl Cancer Inst*, 2001. 93: 597.
<http://www.ncbi.nlm.nih.gov/pubmed/11309436>
180. Giesbers, A.A., *et al.* Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. *Br J Urol*, 1989. 63: 176.
<http://www.ncbi.nlm.nih.gov/pubmed/2495144>
181. Kuroda, M., *et al.* Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUICRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. *Eur Urol*, 2004. 45: 600.
<http://www.ncbi.nlm.nih.gov/pubmed/15082202>
182. Lammers, R.J., *et al.* The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. *Eur Urol*, 2011. 60: 81.
<http://www.ncbi.nlm.nih.gov/pubmed/21531502>
183. Di Stasi, S.M., *et al.* Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol*, 2006. 7: 43.
<http://www.ncbi.nlm.nih.gov/pubmed/16389183>
184. Arends, T.J., *et al.* Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. *J Urol*, 2014. 192: 708.
<http://www.ncbi.nlm.nih.gov/pubmed/24704017>
185. Shelley, M.D., *et al.* A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. *BJU Int*, 2001. 88: 209.
<http://www.ncbi.nlm.nih.gov/pubmed/11488731>
186. Han, R.F., *et al.* Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. *Urology*, 2006. 67: 1216.
<http://www.ncbi.nlm.nih.gov/pubmed/16765182>
187. Shelley, M.D., *et al.* Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. *BJU Int*, 2004. 93: 485.
<http://www.ncbi.nlm.nih.gov/pubmed/15008714>

188. Böhle, A., *et al.* Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol*, 2003. 169: 90.
<http://www.ncbi.nlm.nih.gov/pubmed/12478111>
189. Duchek, M., *et al.* Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. *Eur Urol*, 2010. 57: 25.
<http://www.ncbi.nlm.nih.gov/pubmed/19819617>
190. Järvinen, R., *et al.* Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma *in situ*: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. *Eur Urol*, 2009. 56: 260.
<http://www.ncbi.nlm.nih.gov/pubmed/19395154>
191. Huncharek, M., *et al.* The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. *Am J Clin Oncol*, 2004. 27: 522.
<http://www.ncbi.nlm.nih.gov/pubmed/15596924>
192. Oddens, J.R., *et al.* The effect of age on the efficacy of maintenance bacillus calmette-guerin relative to maintenance epirubicin in patients with stage ta t1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. *Eur Urol*, 2014. 66: 694.
<http://www.ncbi.nlm.nih.gov/pubmed/24948466>
193. Rentsch, C.A., *et al.* Bacillus calmette-guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. *Eur Urol*, 2014. 66: 677.
<http://www.ncbi.nlm.nih.gov/pubmed/24674149>
194. Sengiku, A., *et al.* A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. *J Urol*, 2013. 190: 50.
<http://www.ncbi.nlm.nih.gov/pubmed/23376145>
195. van der Meijden, A.P., *et al.* Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. *Eur Urol*, 2003. 44: 429.
<http://www.ncbi.nlm.nih.gov/pubmed/14499676>
196. Brausi, M., *et al.* Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. *Eur Urol*, 2014. 65: 69.
<http://www.ncbi.nlm.nih.gov/pubmed/23910233>
197. Herr, H.W. Intravesical bacillus Calmette-Guerin outcomes in patients with bladder cancer and asymptomatic bacteriuria. *J Urol*, 2012. 187: 435.
<http://www.ncbi.nlm.nih.gov/pubmed/22177154>
198. Herr, H.W. Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria. *BJU Int*, 2012. 110: E658.
<http://www.ncbi.nlm.nih.gov/pubmed/22883017>
199. Lamm, D.L., *et al.* Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. *J Urol*, 1992. 147: 596.
<http://www.ncbi.nlm.nih.gov/pubmed/1538436>
200. Palou, J., *et al.* Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. *Transplantation*, 2003. 76: 1514.
<http://www.ncbi.nlm.nih.gov/pubmed/14657696>
201. Yossepowitch, O., *et al.* Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. *J Urol*, 2006. 176: 482.
<http://www.ncbi.nlm.nih.gov/pubmed/16813873>
202. Roumeguere, T., *et al.* Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. *Transpl Int*, 2015. 28: 199.
<http://www.ncbi.nlm.nih.gov/pubmed/25377421>
203. Rodriguez, F., *et al.* [Practical guideline for the management of adverse events associated with BCG installations]. *Arch Esp Urol*, 2008. 61: 591.
<http://www.ncbi.nlm.nih.gov/pubmed/18709813>
204. Witjes JA., *et al.* Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. *Eur Urol Suppl*, 2008. 7: 667.
<http://www.sciencedirect.com/science/article/pii/S1569905608001103>

205. Palou, J., *et al.* Intravesical treatment of severe bacillus Calmette-Guerin cystitis. *Int Urol Nephrol*, 2001. 33: 485.
<http://www.ncbi.nlm.nih.gov/pubmed/12230277>
206. Falkensammer, C., *et al.* Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma. *Urology*, 2005. 65: 175.
<http://www.ncbi.nlm.nih.gov/pubmed/15667898>
207. Tinazzi, E., *et al.* Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. *Rheumatol Int*, 2006. 26: 481.
<http://www.ncbi.nlm.nih.gov/pubmed/16220289>
208. Morales, A., *et al.* Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. *J Urol*, 1976. 116: 180.
<http://www.ncbi.nlm.nih.gov/pubmed/820877>
209. Lamm, D.L., *et al.* Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma *in situ* transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol*, 2000. 163: 1124.
<http://www.ncbi.nlm.nih.gov/pubmed/10737480>
210. Zlotta, A.R., *et al.* What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? *Eur Urol*, 2000. 37: 470.
<http://www.ncbi.nlm.nih.gov/pubmed/10765079>
211. Oddens, J., *et al.* Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. *Eur Urol*, 2013. 63: 462.
<http://www.ncbi.nlm.nih.gov/pubmed/23141049>
212. Martinez-Pineiro, L., *et al.* Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. *Eur Urol*, 2015. 68: 256.
<http://www.ncbi.nlm.nih.gov/pubmed/25794457>
213. Martinez-Pineiro, J.A., *et al.* Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. *BJU Int*, 2002. 89: 671.
<http://www.ncbi.nlm.nih.gov/pubmed/11966623>
214. Martinez-Pineiro, J.A., *et al.* Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. *J Urol*, 2005. 174: 1242.
<http://www.ncbi.nlm.nih.gov/pubmed/16145378>
215. Ojea, A., *et al.* A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. *Eur Urol*, 2007. 52: 1398.
<http://www.ncbi.nlm.nih.gov/pubmed/17485161>
216. Solsona, E., *et al.* Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. *Eur Urol*, 2015. 67: 508.
<http://www.ncbi.nlm.nih.gov/pubmed/25301758>
217. Jarvinen, R., *et al.* Long-term Outcome of Patients with Frequently Recurrent Non-muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guerin (BCG) or Alternating BCG and Interferon-alpha2b Instillations: Prospective Randomised FinnBladder-4 Study. *Eur Urol*, 2015. 68: 611.
<http://www.ncbi.nlm.nih.gov/pubmed/25748117>
218. Jakse, G., *et al.* Intravesical BCG in patients with carcinoma *in situ* of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. *Eur Urol*, 2001. 40: 144.
<http://www.ncbi.nlm.nih.gov/pubmed/11528191>
218. Gofrit, O.N., *et al.* The natural history of bladder carcinoma *in situ* after initial response to bacillus Calmette-Guerin immunotherapy. *Urol Oncol*, 2009. 27: 258.
<http://www.ncbi.nlm.nih.gov/pubmed/18440839>

220. Sylvester, R.J., *et al.* Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma *in situ* of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol*, 2005. 174: 86.
<http://www.ncbi.nlm.nih.gov/pubmed/15947584>
221. Kaasinen, E., *et al.* Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma *in situ* of the urinary bladder: a nordic study. *Eur Urol*, 2003. 43: 637.
<http://www.ncbi.nlm.nih.gov/pubmed/12767365>
222. Solsona, E., *et al.* Extravesical involvement in patients with bladder carcinoma *in situ*: biological and therapy implications. *J Urol*, 1996. 155: 895.
<http://www.ncbi.nlm.nih.gov/pubmed/8583601>
223. Palou, J., *et al.* Urothelial carcinoma of the prostate. *Urology*, 2007. 69: 50.
<http://www.ncbi.nlm.nih.gov/pubmed/17280908>
224. Palou Redorta, J., *et al.* Intravesical instillations with bacillus calmette-guerin for the treatment of carcinoma *in situ* involving prostatic ducts. *Eur Urol*, 2006. 49: 834.
<http://www.ncbi.nlm.nih.gov/pubmed/16426729>
225. Herr, H.W., *et al.* Defining bacillus Calmette-Guerin refractory superficial bladder tumors. *J Urol*, 2003. 169: 1706.
<http://www.ncbi.nlm.nih.gov/pubmed/12686813>
226. Lerner, S.P., *et al.* Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. *Urol Oncol*, 2009. 27: 155.
<http://www.ncbi.nlm.nih.gov/pubmed/18367117>
227. van den Bosch, S., *et al.* Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. *Eur Urol*, 2011. 60: 493.
<http://www.ncbi.nlm.nih.gov/pubmed/21664041>
228. Gallagher, B.L., *et al.* Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. *Urology*, 2008. 71: 297.
<http://www.ncbi.nlm.nih.gov/pubmed/18308107>
229. Rosevear, H.M., *et al.* Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma *in situ*. *J Urol*, 2011. 186: 817.
<http://www.ncbi.nlm.nih.gov/pubmed/21788050>
230. Morales, A., *et al.* Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin. *J Urol*, 2015. 193: 1135.
<http://www.ncbi.nlm.nih.gov/pubmed/25286009>
231. Yates, D.R., *et al.* Treatment options available for bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer. *Eur Urol*, 2012. 62: 1088.
<http://www.ncbi.nlm.nih.gov/pubmed/22959049>
232. Dalbagni, G., *et al.* Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. *J Clin Oncol*, 2006. 24: 2729.
<http://www.ncbi.nlm.nih.gov/pubmed/16782913>
233. Mohanty, N.K., *et al.* Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. *Urol Oncol*, 2008. 26: 616.
<http://www.ncbi.nlm.nih.gov/pubmed/18367121>
234. Barlow, L., *et al.* A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. *BJU Int*, 2009. 104: 1098.
<http://www.ncbi.nlm.nih.gov/pubmed/19389012>
235. Steinberg, G., *et al.* Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma *in situ* of the bladder. The Valrubicin Study Group. *J Urol*, 2000. 163: 761.
<http://www.ncbi.nlm.nih.gov/pubmed/10687972>
236. Nativ, O., *et al.* Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. *J Urol*, 2009. 182: 1313.
<http://www.ncbi.nlm.nih.gov/pubmed/19683278>
237. Joudi, F.N., *et al.* Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. *Urol Oncol*, 2006. 24: 344.
<http://www.ncbi.nlm.nih.gov/pubmed/16818189>

238. Di Lorenzo, G., *et al.* Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. *Cancer*, 2010. 116: 1893.
<http://www.ncbi.nlm.nih.gov/pubmed/20162706>
239. Jones, G., *et al.* Intravesical gemcitabine for non-muscle invasive bladder cancer. *Cochrane Database Syst Rev*, 2012. 1: CD009294.
<http://www.ncbi.nlm.nih.gov/pubmed/22259002>
240. Turker, P., *et al.* Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. *BJU Int*, 2012. 110: 804.
<http://www.ncbi.nlm.nih.gov/pubmed/22321341>
241. Chalasani, V., *et al.* Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience. *Can Urol Assoc J*, 2011. 5: 83.
<http://www.ncbi.nlm.nih.gov/pubmed/21470529>
242. May, M., *et al.* Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. *Scand J Urol Nephrol*, 2011. 45: 251.
<http://www.ncbi.nlm.nih.gov/pubmed/21388337>
243. Svatek, R.S., *et al.* Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int*, 2011. 107: 898.
<http://www.ncbi.nlm.nih.gov/pubmed/21244604>
244. Shariat, S.F., *et al.* Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol*, 2007. 51: 137.
<http://www.ncbi.nlm.nih.gov/pubmed/16793197>
245. Bianco, F.J., Jr., *et al.* Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. *Urol Oncol*, 2004. 22: 290.
<http://www.ncbi.nlm.nih.gov/pubmed/15283885>
246. Willis, D.L., *et al.* Clinical outcomes of cT1 micropapillary bladder cancer. *J Urol*, 2015. 193: 1129.
<http://www.ncbi.nlm.nih.gov/pubmed/25254936>
247. Raj, G.V., *et al.* Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. *J Urol*, 2007. 177: 1283.
<http://www.ncbi.nlm.nih.gov/pubmed/17382713>
248. Stein, J.P., *et al.* Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol*, 2001. 19: 666.
<http://www.ncbi.nlm.nih.gov/pubmed/11157016>
249. Hautmann, R.E., *et al.* Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. *J Urol*, 2006. 176: 486.
<http://www.ncbi.nlm.nih.gov/pubmed/16813874>
250. Madersbacher, S., *et al.* Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. *J Clin Oncol*, 2003. 21: 690.
<http://www.ncbi.nlm.nih.gov/pubmed/12586807>
251. Shariat, S.F., *et al.* Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol*, 2006. 176: 2414.
<http://www.ncbi.nlm.nih.gov/pubmed/17085118>
252. Shariat, S.F., *et al.* Characteristics and outcomes of patients with carcinoma *in situ* only at radical cystectomy. *Urology*, 2006. 68: 538.
<http://www.ncbi.nlm.nih.gov/pubmed/16979748>
253. Holmäng, S., *et al.* Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. *J Urol*, 2001. 165: 1124.
<http://www.ncbi.nlm.nih.gov/pubmed/11257652>
254. Fujii, Y., *et al.* Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. *BJU Int*, 2003. 92: 559.
<http://www.ncbi.nlm.nih.gov/pubmed/14511033>
255. Borhan, A., *et al.* Grade progression and regression in recurrent urothelial cancer. *J Urol*, 2003. 169: 2106.
<http://www.ncbi.nlm.nih.gov/pubmed/12771728>
256. Soloway, M.S., *et al.* Expectant management of small, recurrent, noninvasive papillary bladder tumors. *J Urol*, 2003. 170: 438.
<http://www.ncbi.nlm.nih.gov/pubmed/12853794>

257. Gofrit, O.N., *et al.* Watchful waiting policy in recurrent Ta G1 bladder tumors. *Eur Urol*, 2006. 49: 303.
<http://www.ncbi.nlm.nih.gov/pubmed/16413659>
258. Pruthi, R.S., *et al.* Conservative management of low risk superficial bladder tumors. *J Urol*, 2008. 179: 87.
<http://www.ncbi.nlm.nih.gov/pubmed/17997444>
259. Holmäng, S., *et al.* Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. *J Urol*, 2002. 167: 1634.
<http://www.ncbi.nlm.nih.gov/pubmed/11912378>
260. Mariappan, P., *et al.* A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. *J Urol*, 2005. 173: 1108.
<http://www.ncbi.nlm.nih.gov/pubmed/15758711>
261. Soukup, V., *et al.* Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. *Eur Urol*, 2012. 62: 290.
<http://www.ncbi.nlm.nih.gov/pubmed/22609313>
262. Holmäng, S., *et al.* Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years? *Eur Urol*, 2012. 61: 503.
<http://www.ncbi.nlm.nih.gov/pubmed/22119022>

10. CONFLICT OF INTEREST

All members of the Non-Muscle-Invasive Bladder Cancer guidelines working group have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publically accessible through the European Association of Urology website: <https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/?type=panel>. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.